PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 1
A PHASE 2A, RANDOMIZED ,DOUBLE -BLIND ,PARALLEL GROUP ,
PLACEBO -CONTROLLED, MULTI- CENTER STUDY TO ASSE SS THE 
EFFICACY AND SAFETY PROFILE OF PF -06651600 IN SUBJECTS WITH 
MODERATE TO SEVERE ACTIVE RHEUMATOID AR THRITIS WITH AN 
INADEQUATE RESPONSE TO METHOTRE XATE
Investigational Product Number: PF-06651600
Investigational Product Name: Not Applicable (N/A)
United States (US) Investigational N ew 
Drug (IND) Number:131274
European Clinical Trial sDatabase 
(EudraCT) Number:2016-002862-30
Protocol Number: B7981006
Phase: 2a
 
 
 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 2Document History
Document Version Date Summary of Changes and Rationale
Amendment 1 26October 2016 In the Schedule of Activities, and 
Section 7.2.12, added audiogram testing
Rationale: To monitor for potential 
changes in hearing between baseline 
[between Visit 1 and Visit 2 
(inclusive)] and at the end of the study  
[between Visit 7 and Visit 9 
(inclusive )
].
The following exclusion criteria has been 
added in Section 4.2:
Have current or recent history of clinically 
significant severe or progressive hearing loss 
or auditory disease. Subjects with hearing 
aids will be allowed to enter the study 
provided their hearing impairment is 
considered controlled/ clinically stable. 
Rationale:  This has been added to 
ensure that subject hearing for safety  
is fully  evaluated prior to study  entry .
Several addit ional minor changes were made 
to protocol language for the purposes of 
clarification.
Original protocol 31August 2016 Not a pplicable ( N/A )
This amendment incorporates all revisions to date, including amendments made at the 
request of country  health au thorities and institutional review boards (I RBs)/ethics committees 
(ECs).  

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 3TABLE OF CONTENTS
LIST OF TABLES .....................................................................................................................7
LIST OF FIGURES ...................................................................................................................8
APPENDI CES ...........................................................................................................................8
PROTOCOL  SUMMARY .........................................................................................................9
SCHEDUL E OF ACTIVITI ES................................................................................................13
1. INTRODUCTION ...............................................................................................................18
1.1. Mechanism of Action/I ndication .............................................................................19
1.2. Background and Rationale
......................................................................................19
1.3. Non
-Clinical Pharmacokinetics, Metabolism of PF -06651600 ..............................19
1.4. Non
-Clinical Safet y Studies with PF -06651600 .....................................................20
1.5. Summary  of Clinical Experience with PF -
06651600 .............................................21
1.5.1. Summary  of Clinical Safet y of PF -06651600 ............................................22
1.5.2. Pharmacokinetics of PF
-06651600.............................................................23
1.6. Summary .................................................................................................................25
1.6.1. Study Rationale ...........................................................................................25
1.6.2. Dose Rationale ............................................................................................25
1.6.3. Summary  of Benefits and Risks .................................................................27
1.6.4. Additional I
nformation ...............................................................................27
2. STUDY OBJECTIVES AND ENDPOINTS .......................................................................27
3. STUDY DESIGN .................................................................................................................29
4. SUBJEC
T ELIGIBILITY CRI TER IA.................................................................................30
4.1. I nclusion Criteria .....................................................................................................30
4.2. Exclusion Criteria
....................................................................................................32
4.3. L ifesty le Requirements ...........................................................................................36
4.3.1. Contraception ..............................................................................................36
4.4. Sponsor’s Qualified Medical Personnel ..................................................................37
5. STUDY TREATMENTS ................................ ................................ ................................ .....38
5.1. Allocation to Treatment ..........................................................................................38
5.2. Breaking the Bl
ind..................................................................................................39
5.3. Subject Compliance .................................................................................................39
5.4. I nvestigational Product Supplies .............................................................................39

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 45.4.1. Dosage Form(s) and Packaging..................................................................39
5.4.2. Preparation and Dispensing ........................................................................40
5.5. Administration .........................................................................................................40
5.6. I nvestigational Product Storage ..............................................................................41
5.7. I nvestigational Product Accountabilit y
...................................................................41
5.7.1. Destruction of Investigational Product Supplies
........................................42
5.8. Background and Concomitant Treatment(s) ...........................................................42
5.8.1. Permitted Background Arthritis Therap y
...................................................42
5.8.2. Prohibited Background Arthritis Therap y
..................................................43
5.9. Rescue Medication ..................................................................................................46
6. STUDY PROCEDURES
.....................................................................................................46
6.1.Screening .................................................................................................................47
6.2. Treatment Period .....................................................................................................47
6.3. Follow -up/End of Study ..........................................................................................47
6.4. Subject Withdrawal/Earl y Withdrawal ...................................................................47
6.4.1. Withdrawal of Consent ...............................................................................47
6.4.2. L ost to Follow -
up .......................................................................................48
7. ASSESSMENTS ..................................................................................................................48
7.1. Efficacy  Assessments ..............................................................................................48
7.1.1. American College of Rheumatology  (ACR) Assessments .........................48
7.1.2. Tender/Painful Joint Cou nt (68) .................................................................49
7.1.3. Swollen Joint Count (66)
............................................................................49
7.1.3.1. Tender and Swollen Joint Counts (28) ......................................50
7.1.4. Patient’s Assessment of Arthritis Pain 
(PAAP)..........................................50
7.1.4.1. Patient’s Global Assessment (PtGA) of Arthritis .....................50
7.1.4.2. Phy sician’s Global Assessment (PhGA) of Arthritis ................50
7.1.4.3. High Sensitivity  C-
Reactive Protein (CRP) ..............................50
7.1.4.4. Ery throcy te Sedimentation Rate (ESR) .....................................51
7.1.4.5. Health Assessment Questionnaire –Disability  Index 
(HAQ -DI)
..........................................................................................51
7.1.5. Composite Efficacy Assessments Derived from the ACR Core 
Dataset ..............................................................................................................51
7.1.5.1. Simple Disease Activity  Index (SDAI) Assessment .................51

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 57.1.5.2. ACR Responder Analy sis..........................................................51
7.1.6. Disease Activity  Score (DAS) Assessments ...............................................51
7.2. Safet y and other Assessments .................................................................................52
7.2.1. Clinical Safety  and Other Laboratory  Tests ...............................................52
7.2.2. Phy sical Examination .................................................................................53
7.2.3. Medical History , Height and Weight ..........................................................53
7.2.4. Pregnancy  Testing ......................................................................................54
7.2.5. Vital Signs (Blood Pressur e, Pulse Rate and Temperature) .......................54
7.2.6. Electrocardiogram .......................................................................................55
7.2.7. I nterferon -Gamma Release Assay ..............................................................55
7.2.8. Chest X -Ray................................................................................................55
7.2.9. I nfection Monitoring ...................................................................................56
7.2.10. Viral Surveillance
.....................................................................................56
7.2.11. Dermatological Assessments
....................................................................57
7.2.12. Audiogram ................................................................................................58
7.3. Pharma cokinetics ....................................................................................................59
7.3.1. Shipment of Pharmacokinetic Samples ......................................................59
7.4. Exploratory  Biomarkers ..........................................................................................59
7.4.1. I FN-gamma -
inducible protein 10 (IP-10)...................................................59
7.4.2.
Anti- CCP and Rheumatoid Factor ..............................................................59
7.4.3. Samp les for Exploratory  Fluorescence Activated Cell Sorting 
(FACS) analy sis...............................................................................................59
7.5. Banked Biospecimens .............................................................................................60
7.5.1. Shipment of Biomar kers Samples ..............................................................61
7.5.2. Additional Research ................................ ................................ .................... 61
7.6. Rater Qualifications.................................................................................................61
8. ADVERSE EVENT REP ORTI NG......................................................................................62
8.1. Requirements ...........................................................................................................62
8.1.1. Additional Details on Recording Adverse Events on the CRF ...................63
8.1.2. Eliciting Adverse Event Information ................................ .......................... 63
8.1.3. Withdrawal From the Study  Due to Adverse Events (see also the 
Subject Wit hdrawal/Early Withdrawal section) ................................ .............. 63
8.1.4. Time Period for Collecting AE/SAE I nformation ......................................63

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 68.1.4.1. Reporting SAEs to Pfizer S afety ...............................................64
8.1.4.2. Recording Non -serious AEs and SAEs on the CRF .................64
8.1.5. Causality  Assessment .................................................................................64
8.1.6. Sponsor’s Reporting Requirements to Regulatory  Authorities ..................64
8.2. Definitions
...............................................................................................................65
8.2.1. Adverse Events ...........................................................................................65
8.2.2. Abnormal Test Findings
.............................................................................65
8.2.3. Serious Adverse Events ..............................................................................66
8.2.4. Hospitalization ............................................................................................66
8.3. Severity  Assessment ................................................................................................68
8.4. Special Situations ....................................................................................................68
8.4.1. Protocol
-Specified Serious Adverse Events ...............................................68
8.4.2. Potential Cases of Drug -
Induced Liver Injury............................................68
8.4.3. Exposure to the Investigational Product During Pregnancy  or 
Breastfeeding, and Occupational Exposure
.....................................................70
8.4.3.1. Exposure During Pregnancy ......................................................70
8.4.3.2. Exposure During Breastfeeding ................................................71
8.4.3.3. Occupational Exposure .............................................................71
8.4.4. Medica tion Errors .......................................................................................72
8.4.4.1. Medication Errors ......................................................................72
9. DATA ANALYSI S/STA TISTICAL  METHODS ...............................................................72
9.1. Sample Size Determination .....................................................................................73
9.2. Efficacy  Anal ysis....................................................................................................73
9.2.1. Analy sis of the Primary  Endpoint ...............................................................73
9.2.2. Analy sis of Secondary  Endpoints ...............................................................74
9.3. Analy sis of Other Endpoints ...................................................................................74
9.4. Randomization ........................................................................................................74
9.5. Safet y Anal ysis........................................................................................................74
9.6. Data Monitoring Committee ...................................................................................74
9.7. PK/PD Unblinding Plan
..........................................................................................74
9.8. Unblinding for Biomarkers .....................................................................................75
10. QUALITY CONTROL  AND QUALITY ASSURANCE ................................ ................. 75

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 711. DATA HANDLING AND RECORD KEEPING .............................................................76
11.1. Case Report Forms/Electronic Data Record .........................................................76
11.2. Record Retention ...................................................................................................76
12. ETHI CS..............................................................................................................................77
12.1. I nstitutional Review Board/Ethics Committee ......................................................77
12.2. Ethical Conduct of the Study ................................................................................77
12.3. Subject I nformation and Consent ..........................................................................77
12.4. Reporting of Safet y Issues and Serious Breaches of the Protocol or ICH 
GCP ...........................................................................................................................78
13. DEFI NITION OF EN D OF TRIAL ...................................................................................78
13.1. End of Trial in a Member State
.............................................................................78
13.2. End of Trial in All Other Participating Countries .................................................79
14. SPONSOR DI SCONTI NUATIO N CRITERIA ................................................................79
15. PUBLICATION OF S TUDY RESUL TS..........................................................................79
15.1. Communication of Results by  Pfizer ....................................................................79
15.2. Publications by  Investigators ................................................................................80
16. REFERENCES ..................................................................................................................81
LIST OF TABLES
Table 1. Skin and Subcutaneous Tissue Disorder Occurrence ...........................................22
Table 2. Summary  of Plasma PF -06651600 Pharmacokinetic Parameters Following 
Single Oral Doses, Study B7981001
....................................................................23
Table 3. Summary  of Plasma and Urine PF
-06651600 Pharmacokinetic Parameters 
Following Multiple Dose Administration for 14 day s, Study  B7981001 .............24
Table 4. Summary  of Predicted Stead y State Plasma Pharmacokinetic and 
Pharmacod ynamic Parameters Following Multiple Dose Administration of 
PF
-06651600.........................................................................................................26
Table 5. Summary  of the Predicted Average Percent In Vitro Signaling I nhibition 
Based on Stead y State PK from 200 mg PF -
06651600........................................26
Table 6. Safety  and other Laboratory  Tests ................................ ................................ ........ 52
Table 7. Management of Dermatological Events ...............................................................57

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 8LIST OF FIGURES
Figure 1. Study  Design Schematic .......................................................................................29
APPENDICES
Appendix 1. Abbreviations ......................................................................................................84
Appendix 2.2010 ACR/EULAR Classification Criteria for Rheumatoid Arthritis24,25..........87
Appendix 3. Criteria for Classification of Functional Status in Rheumatoid Arthritis26.........89
Appendix 4. Prohibited Concomitant Medications
..................................................................90
Appendix 5. Guidelines for Monitoring and Discontinuations ................................................92
Appendix 6. Disease Activity  Score (DAS) Assessments1......................................................94
Appendix 7. Patient’s Assessment of Arthritis Pain (PAAP) ..................................................95
Appendix 8. Patient’s Global Assessment (PtGA) of Arthritis
...............................................96
Appendix 9. Phy sician’s Global Assessment (PhGA) of Arthritis ..........................................97
Appendix 10. Oral Corticosteroid Equivalents28,29,30,31,32........................................................98
Appendix 11. Allowed Opioids and Approximate Equivalent Morphine Doses Of 
Opioid Analgesics33,34...........................................................................................99
Appendix 12. Common Terminology  Criteria for Adverse Events v4.03 
(CTCAE) -Dermatology ......................................................................................100
Appendix 13. HAQ -DI35........................................................................................................102
Appendix 14. Assessment of I tch (NRS)36............................................................................105

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 9PROTOCOL SUMMARY
Background and Rationale :
PF-06651600 is a potent, Janus kinase (JAK) 3 selective, covalent inhibitor.  I t is an orally  
bioavailab le small molecule that selectivel y inhibits JAK3 by  irreversibly  blocking the 
adenosine triphosphate (ATP) binding site without significantly  inhibiting the other three 
JAK isoforms (JAK1, JAK2, and TYK2).   The molecule also has a high specificity  against 
the broad human kinome. 
This JAK3-selective inhibition will lead to modulation of -common chain cy tokine 
pathway s, such as IL-7, IL -9, IL -15 and IL -21, some of which have been implicated in the 
pathophy siology  of Rheumatoid Arthritis ( RA).  PF-06651600 w ill spare inhibition of key
immuno -regulatory cytokines, such as IL -10, IL -35 which play  a protective role in RA.   
Inhibition of JAK2 cy tokine signaling, implicated to be associated with adverse effects such 
as neutropenia, thrombocy topenia and anemia14will also be spared, thus making 
JAK3 -selective inhibitors an attractive therapeutic modality . JAK3 is also expressed onl y in 
the hematopoietic cells and thus the rationale for improved therapeutic index of PF -06651600 
in RA over pan
-JAK inhibition.   This multicenter, placebo controlled stud y will be the first 
determination of safet y and efficacy of PF -06651600 in subjects with moderate tosevere 
active RA who have had an 
inadequate response to methotrexate (up to approximately  50% 
of subjects may  also have had an inadequate response to 1 anti- TNFbiologic DMARD) . 
Objectives and Endpoints:
Prim ary Objectives: Prim ary Endpoints:
To evaluate the efficacy of PF -06651600 
at 8weeks in subjects with moderate to 
sever e active RA.Change from baseline in Simple Disease Activity
Index (SDAI) at Week 8.
Secondary Objectives: Secondary Endpoints:
To evaluate the safety of PF -06651600. Safety and tolerability of PF -06651600 versus 
placebo ; vital signs, laboratory tests, adverse events 
(AEs) including infections and Serious Adverse 
Events (SAEs) .
To assess other signs of clinical efficacy 
over 8 weeks.Change from baseline in SDAI at Weeks 1, 2, 4 and 6 .
Change from baseline in SDAI low  disease activity 
scale (LDAS) and re mission rates at Week 4, Week 6 
and Week 8.
Change from baseline in DAS28 LDAS and remission 
rates at Week 4, Week 6 and Week 8.
The following will also be calculated at Weeks 1, 2,4, 6 
and 8:
Change from baseline in DAS28 -3 (ESR), DAS28 -3 
(CRP), DAS28 -4(ESR), and DAS28 -4 (CRP).

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 10Change from baseline in hsCRP.
Change from baseline in the Tender/Painful and 
Swollen Joint Count (28).
Change from baseline in the Physician Global 
Assessment of Arthritis.
To assess the effect of PF-06651600 on 
patient reported outcome measurements.Change from baseline in the Patient’s Assessment of 
Arthritis Pain (VAS) and Patient Global Assessment of Arthritis (VAS) at Weeks 1, 2, 4, 6 and 8.
Change from baseline in the HAQ-DI at Weeks 1, 2, 
4, 6 and 8.
  
 
 
 
   
  
 
  
 
 
 
 Change from baseline in ACR 20, ACR 50 and 
ACR 70 responder rates.
  
*Note: (Analysis of exploratory endpoints may be further detailed in the statistical analysis plan (SAP) or 
exploratory analysis plan (EAP).  Samples collected for exploratory endpoints may or may not be analyzed and, if analyzed, may or may not be reported in the CSR.)CCI
CCICCI
CCI
PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 11Study Design and Treatments :
Study Design Schematic
Note:  N indicates the total number of completer s.
This is a Phase 2a, 8 week randomized double -blind, parallel group, placebo controlled, 
multi-center study  to assess the efficacy  and safety  profile of PF -06651600 in seropositive 
subjects with moderate to severe active rheumatoid arthritis with an inad equate response to 
methotrexate (up to approximately  50% of subjects may  also have had an inadequate 
response to 1 anti -TNFbiologic DMARD)
. 
Up to approximatel y 60 subjects may  berandomized globally  into the study to ensure at least 
approximatel y 50 subjects complete 8 weeks of active dosing (assuming a dropout rate of 
approximatel y 15%).   Subjects will participate in this study  for approximately  17weeks.  
This includes an up to 5-week screening period, an 8 week treatment period, and a 4 week 
follow -
upperiod. 
After an up to 5 week screening period, eligible subjects will be randomized to receive 
200mg QD of PF -06651600 or placebo (matching tablets for PF- 06651600 QD) every  day 
for 8 weeks in a blinded fashion. 
Statistical Methods :
Analysis of Primar y Endpoint
The p rimary  efficacy  analy sis will be conducted on Simple Disease Activity Index ( SDAI )
change from baseline at 8 weeks. 
Analy sis will include data on PF -06651600 and placebo arms. 
Analy sis details will be outlined in statistical analy sis plan (SAP) .  The analy sis will include: 
Analy sis of Covariance (ANCOVA )models adjusting for SDAI baseline value; Bay esian PF-06651600 , 2 00 mg QD, N = 308 Weeks
Dosing
5 Weeks 
Screening4 Weeks 
Follow UpPlacebo QD, N = 20

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 12analysis of posterior distributions of the SDAI  scores and placebo adjusted change from 
baseline; Advanced data visualization techniques for statistical result presentation. 
The primary  anal ysis will be conducted on intention -to-treat (ITT) population (randomized 
subjects with at least one post baseline value).   Sensitivity  analy sis and handling of the 
missing values will be outlined in the SAP.
Analysis of Secondary Endpoints
Analy ses of the secondary  endpoints will be outlined in the SAP.
  Continuous and discrete 
modeling techniques will be applied whenever applicable.  The statistical summaries will be 
presented b y dose groups.  The corr elations between the endpoints will be anal yzed. 
Analysis of Other Endpoints
Analy sis of other endpoints will be conducted as deemed appropriate.  Continuous and 
discrete modelling techniques will be applied whenever applicable.  Distribution summaries 
will be presented b y means of summary tables data visualization methods.
Safety Analysis
All clinical Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Emergent 
Adverse Events ( TEAEs), withdrawal due to AEs, e
lectrocardiograms (ECGs), vital signs 
and safet y laboratory
 data will be reviewed and summarized on an ongoing basis during the 
study  to evaluate the safety  of subjects. 
The safet y analysis set will include all subjects who have received at least one dose of IP.  
Safety  data will be present ed in tabular and/or graphical format and summarized 
descriptivel y, where appropriate.  All safet y endpoints will be listed and summarized in 
accordance with Pfizer Standards.  Categorical outcomes (eg, AEs) will be summarized by  
subject counts and percent age.  Continuous outcome (eg, blood pressure (BP) , pulse rate, etc) 
will be summarized using N, mean, median, standard deviation, etc.  Change from baseline in 
laboratory  data, ECGs and vital signs will also be summarized.  Subject listings will be 
produce d for these safet y endpoints accordingl y. 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 13SCHEDULE OF ACTIVITI ES
The schedule of activities table provides an overview of the protocol visits and procedures.  Refer to the STUDY PROCEDURES and 
ASSESSMENTS sections of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol .
The investigator may  schedule visits (unplanned visits ) inaddition to those listed on the schedule of activities table , in o rder to 
conduct evaluations or assessments required to protect the well -being of the subject.
Protocol ActivityScreening Treat ment Period Follow Up/End of 
StudyEarly
Withdrawalb
Visit Identifier 1 2 3 4 5 6 7 8s9
WeekaWeek 0 Week 1 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12
Study Day Days -35 to Day 0 Day 1xDay 8 Day 15 Day 29 Day 43 Day 57 Day 71 Day 85
Visit Window 2 Days based on Week 0/Day 1 visit
Informed consent X
Inclusion/Exclusion Criteria X X
Demographics and RA history X
Prior RA medications checkcX X
Smoking History X
Medical history and Non RA medications X
History of Alcohol and Drug Abuse X
HeightvX
WeightvX X X
Contraception CheckrX X X X X X X XsX X
Vital Signs ( pulserate, blood pressure), 
temperatured X X X X X X X X X
Complete Physical ExaminationeX X X X
Targeted Physical ExaminationeX X X X X
Rash assessment X X X X X X X XsX X
ECG (12 lead)fX X X X X
Chest X -raygX
AudiogramyX X X
Laboratory Evaluations
Blood ChemistryhX X X X X X
Hematology X X X X X X X X X
Rheumatoid Factor (RF) X X X X X X
C-Reactive Protein ( hsCRP) X X X X X X X X X

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 14Protocol ActivityScreening Treat ment Period Follow Up/End of 
StudyEarly
Withdrawalb
Visit Identifier 1 2 3 4 5 6 7 8s9
WeekaWeek 0 Week 1 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12
Study Day Days -35 to Day 0 Day 1xDay 8 Day 15 Day 29 Day 43 Day 57 Day 71 Day 85
Visit Window 2 Days based on Week 0/Day 1 visit
Anti CCP Antibodies (ACPA) X X X X X X
Erythrocyte Sedimentation Rate 
(ESR)X X X X X X X X
Serum Ig (IgA, IgM, IgG) X X X
Serum IgE X X X
Sample for IP -10 X X X X
Urinalysis X X X X X X X X X
Pregnancy testiX X X X X X X X X
FSH test (if applicable)tX
HBsAg, H BcAb, HBsA band 
HCVAb antibodyj X
HIV testingkX
HbA1c X
Tuberculosis testlX
Viral SurveillanceuX X X X X X X X X
Sample for flow cytometry X X X
Banked RNA biospecimen 
(Prep R1)m X X X X
Banked plasma biospecimens 
(Prep B1)m X X X X
Banked serum biospecimens 
(Prep B2)m X X X X
Genomic banked biospecimen 
(Prep D1)q,m X
Study Treat ment
Randomization (after all screening 
procedures are complete and 
reviewed) X
Administration and Dispensing of 
PF-06651600 or Placeboo X X X X X X
Investigational Product 
AccountabilityX X X X X X

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 15Protocol ActivityScreening Treat ment Period Follow Up/End of 
StudyEarly
Withdrawalb
Visit Identifier 1 2 3 4 5 6 7 8s9
WeekaWeek 0 Week 1 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12
Study Day Days -35 to Day 0 Day 1xDay 8 Day 15 Day 29 Day 43 Day 57 Day 71 Day 85
Visit Window 2 Days based on Week 0/Day 1 visit
Review of subject diary (review of 
subjects dosing record), IP
accountability and compliance 
check throughout the studypX X X X X X X
Phar macokinetic
Pre-dose (0hr) blood sample for PK 
analysis of PF -06651600 X X X X X X Xw
Blood sample for PK analysis of 
PF-06651600  (0.5 hr) post doseX X X X
Blood sample for PK analysis of 
PF-06651600 at 1 hr post doseX X X
Blood sample for PK analysis of 
PF-06651600 at 2 and 4 hr post 
doseX
Efficacy assessments 
Tender/Painful Joint Count (68) X X X X X X X X X
Swollen Joint Count (66) X X X X X X X X X
Patient Assessment of Arthritis 
Pain (PAAP) VASX X X X X X XXX
Patient ’sGlobal Assessment 
(PtGA) of Arthritis VASX X X X X X XXX
Physician ’sGlobal Assessment 
(PhGA) of Arthritisn X X X X X X XXX
Health Assessment Questionnaire –
Disability Index (HAQ -DI)X X X X X X XXX
Serious and Non -Serious Adverse Event 
AssessmentX       X X X
Concomitant Medication & Treatments X      X X X
Discharge from the study X X
Abbreviations: = ongoing/continuous event; CRP = C -Reactive Protein; DNA = deoxyribonucleic acid ; ECG = electro cardiogram; EOS = end of st udy; ESR 
= Erythrocyte Sedimentation Rate; FACS = fluorescence -activated cell sorting; FSH = follicle stimulating hormone; HAQ -DI = Health Assessment 
Questionnaire –Disability Index; HBcAb = hepatitis B core antibody; HBsAg =hepatitis B surface antigen; HBsAb= hepatitis B surface antibody; 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 16HCVAb = hepatitis C antibody; HIV =human immunodeficiency virus;  hsCRP =high-sensitivity C -reactive protein; IgA, Ig G, IgM, IgE = Immunoglobulin of 
the A, G, M, E isot ypes; IGRA = Interferon Gamma R elease Assay; IP = investigational product; IP -10 = IFN -gamma -inducible protein 10; IRB = institutional 
review board; PK = pharmacokinetic; PAAP = Patient Assessment of Arthritis Pain; PtGA = patient ’sglobal assessment ; PhGA = Physician ’sGlobal 
Assessment; PK=Pharm acoki netics; RNA = Ribonucleic Acid; VAS = Visual Analog Scale; WONCBP = w omen of non -childbearing potential .
a.Visits should occur when scheduled, w ithin the time window indicated in the column headings.  The screening visit is up to 5 weeks prior to Visit 2. On all 
clinic visit days, PtGA and PAAP VAS measures and HAQ -DI questionnaires, should be performed prior to any other assessments.   Vital signs, ECG and 
blood draws should be performed as specified in Section 7.  Assessments including joint counts , physician questionnaire, and pre-dose blood collections are 
to be performed prior to dosing unless otherwise stated.   Physician’s assessment should be performed without knowledge of patient reported VAS 
assessments Additional unscheduled assessments should be performed as clinically indicated.
b.See Section 6.4for guidelines on subject w ithdrawal/early withdrawal from the study.   Any subj ect w ho prematurely withdraws from the treatment period 
should undergo the procedures for an early withdrawal visit and return for follow  up visits if medically needed in the opinion of the PI .  Document reasons 
for Early Withdrawal.
c.Check and verify prior and current RA medications taken after informed consent issigned to ensure compliance with protocol eligibility criteria. Written 
informed consent must be obtained prior to performing any washout of prohibited medication.
d.See Section 7.2.5 for guidelines on measurement of vital signs.
  The same measurement method should be used consistently throughout the study . 
e.All subjects will have a dermatological full body exam at Screening Visit. Addi tional Physical Exams ( P
Es)may be performed during the study at the 
investigator’s discretion.   See Section 7.2.2 forguidelines on collecting PEs.
f.An ECG may be performed at other times, at the discretion of the investigator if there were findings during a previous examination or in the case of a 
new/open adverse event (AE) .  See Section 7.2.6 for guidelines on ECGs. 
g.See Section 7.2.8 for guidelines on Chest X -rays.
h.A minimum of 8 -hour fasting is required for lipid profile evaluation at Day 1, W eek4, W eek8, and EOS.  Laboratory tests may be repeated once during the
screening period; the last value w ill be used to determine eligibility .  See Section 7.2.1 foradditional information on blood chemistry collection. 
i.Required for w omen of childbearing potent ial who do not meet the definition of non- childbearing potential as per the inclusion/exclusion criteria.   Serum  
pregnancy test must be performed at screening. Pregnancy tests (serum/urine) may also be repeated more frequently as per request of IRBs/ECs or if 
required by local regulations. See Section 7.2.4 .
j.See Section 
4forsubject eligibility criteria. 
k.HIV testing per local re gulations.   See Section 4forsubject eligibility criteria.
l.IGRA official reading and method, or test as per country specific guidelines, must be located in source documentation.   See Section 4 forsubject eligibility 
criteria.
m.These samples must be collected before administration of the investigational product.   See Section 7.5for details.
n.Physician ’sassessment should be performed without knowledge of patient reported VAS assessments. 
o.At the baseline visit, (Visit 2) the first dose of investigational product will be taken in the clinic.  Additionally, at Weeks 1, 2,4, 6 and 8 subjects should be 
given their dose for that day in the clinic .  All other doses will be taken by the subject outside of the clinic.
p.Subject diary dispensed and/or collected.  Subject diary, study compliance and investigational product administ ration entries 
are reviewed. See Section 5.3.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 17q.If not collected on the designated collection day, collect at the next available time point when biospecimens are being colle cted in conjunction with a subject 
visit.
r.Except for w omen of non -child bearing potential .See Section 4.3.1 and Section 7.2.4 .
s.Telephone follow up.  Adverse Event and r ash assessment s (if needed) will be conducted verbally over the phone and if needed subject w ill be asked to 
come in for AE assessment.   Use of contraception will be confirmed 
and concomitant medication check will be done over the p hone with the subject. 
t.To confirm postmenopausal status (if applicable) .
u.In addition to time points specified, a plasma sample for viral surveillance sample may also be taken at the time of an adver se event. See Section 7.2.10 for 
details. 
v.Height and Weight will be measured without shoes. 
w.At the time of the visit, a b lood sample will be collected for PK analysis.   As with all PK assessments, d ate and time of last dose and date and time of sa mple 
collection should be captured and reported . 
x.Baseline Visit .
y.Audiogram testing at screening must be completed and results available by the baseline visit (Visit 2) and audiogram testing at Week 8 (Visit 7) must be 
completed and results available by th e Week 12 visit (Visit 9). For subjects that terminate early from the study, if possible, efforts must be made to complete 
the audiology testing and obtain the results. See Section 7.2.12 for details.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 181. INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, autoimmune disease characterized by  joint 
inflammation and destruction, progressive disability  and adverse psy chological effects.  The 
prevalence of RA is approximately  0.5-1% of the popula tion indeveloped regions with a 
4-fold higher frequency  in women than in men .16  There is considerable evidence for both 
genetic and environmental contributions to RA.  A growing body  of evidence has implicated
anti-citru
llinated protein antibodies (ACP A) in more severe manifestations of RA.  ACPA 
positive (ACPA+) RA subjects tend to have more rapidly  progressing disease and are less 
likely  to respond to current therap y.20
There are multiple therapeutic options for managing the pain and slowing the progression of 
rheumatoid arthritis, but none completel y cure the disease.  The current goal of treatment (as 
stipulated in the 2010 European League Against Rheumatism (EUL AR) recommendations 
for the treatment of RA )aims toward achieving the lowest possible level of arthritis disease 
activity  (ideally , remission), minimizing joint damage, and enhancing phy sical function and 
quality  of life .17  Disease -modify ing antirheumatic drugs (DMARDs) are the standard 
treatments for RA.
  Conventional sy nthetic DMARDs (csDMARDs), such as methotrexate, 
are used either alone or in combination with newer biologic DMARDs.   They  work to 
decrease pa in and inflammation, to reduce or prevent joint damage, and to preserve the 
structure and function of the joints but rarely  induce remission.
  Use of biologic DMARDs, 
most commonly  TNFinhibitors, is indicated when sy mptoms are not adequately  controlled 
with csDMARDs.  Additional approved therapeutics include tocilizumab (interleukin (IL) -6 
receptor neutralizing antibody ) and tofacitinib (a small molecule pan -Janus kinase (JAK) 
inhibitor).   Despite the considerable list of approved treatments for RA, there are significant 
numbers of 
subjects who do not achieve remission or achieve adequate reduction in disease 
activity .5
Tofacitinib , approved b y the Food and Drug Administration ( FDA )in 2012 is the first JAK 
inhibitor for the treatment of moderate -to-severe RA .  It is a pan -JAK inhibitor with 
inhibitory  activit yranked in the ord er JAK3 > JAK1 >JAK2 > TYK2 .  The broad inhibitory  
effect on JAK3, JAK1, JAK2 and TYK2 impacts a broad panel of cy tokine signaling 
path
waysincluding cy tokines with anti -inflammatory  roles such as IL -10.  Tofacitinib 
blockade of JAK2, also results insome of the treatment- associated 
adverse effects such as 
anemia and neutropenia.14Thus ,the rationale for selective JAK3 inhibition.  This rationale 
is additionally  supported by  the fact that JAK3 deficiency  in mice and humans results in 
immunodeficiency  due to lack of circulating NK and T cells.  Selectivel y expression of JAK3 
in hematopoietic ce lls and its essential role in ly mphocy te development lends support for 
JAK3 as a target for immune suppression.9,3,12,18
The JAK family  of kinases mediate ssignal transduction via interactions with ty peI and 
typeII cytokine receptors.  Several JAK3 cy tokines such as IL -15, IL -7, IL -9 and IL -21 have
been implicated in RA .21
,6,19  Roles for IL -15 and IL-7 in the pathogenesis of RA have been 
demonstrated in mouse models.   Furthermore, levels of thes e cytokines are also reported to 
be elevated in blood/serum andsynovial fluid in RA subjects and IL -
7 and IL - 21 cytokines 
also promot eosteoclastogenesis.  Hence the rationale to target JAK3 -mediated cy tokine 
signaling pathway s.  Additional support for the rationale for JAK3 inhibition in RA comes

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 19from several human clinical studies with HuMax-IL-15 (AMG714), a neutralizing antibody 
against IL-15 and decernotinib (VX-509, a JAK3-selective inhibitor).2,4,16,11,10,8  Therefore 
blocking signaling downstream of JAK3 may be beneficial in RA.
1.1. Mechanism of Action/Indication
PF-06651600 is a potent and selective covalent inhibitor of JAK3 that is currently under 
development for the treatment of RA and Ulcerative Colitis (UC).
1.2. Background and Rationale
PF-06651600 is a potent, Janus kinase (JAK)3 selective, covalent inhibitor. It is an orally 
bioavailable small molecule that selectively inhibits JAK3 by irreversibly blocking the adenosine triphosphate (ATP) binding site without significantly inhibiting the other three JAK isoforms (JAK1, JAK2, and TYK2).  The molecule also has a high specificity against the broad human kinome.
This JAK3-selective inhibition will lead to modulation of -common chain cytokine 
pathways, such as IL-7, IL-9, IL-15 and IL -21, some of which have been implicated in the 
pathophysiology of RA.  PF-06651600 will spare inhibition of key immuno-regulatorycytokines, such as IL-10, IL-35 which play a protective role in RA.  Inhibition of JAK2 cytokine signaling, implicated to be associated with adverse effects such as neutropenia, thrombocytopenia and anemia
14will also be spared, thus making JAK3-selective inhibitors 
an attractive therapeutic modality.  JAK3 is also expressed only in the hematopoietic cells and thus the rationale for improved therapeutic index of PF-06651600 in RA over pan-JAK inhibition. 
 
  
 
 
 
 
 
 
 
 
  
 
 CCI
PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 20 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 21 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 CCI
CCI
PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 221.5.1. Summary of Clinical Safety of PF -06651600
Eighty  (80) subjects were enrolled into the FIH study .  Single doses up to 800 mg and 
multiple doses up to 400 mg daily , as both 400 mg QD and 200 mg BID were administered.  
PF-06651600 appears to be gener ally safe and well -tolerated.  No clinically -significant 
changes in vital signs, electrocardiogram or laboratory  data were observed.  No dose -limiting 
adverse events were reported and no subjects met the protocol prescribed individual stopping 
rules.  Ther e were no deaths in the study . 
The most commonly  reported all causality  treatment -emergent AEs across both Single 
Ascending Dose ( SAD )and Multiple Ascending Dose ( MAD )PF-06651600 cohorts were GI 
disorders ,including diarrhea (9 subjects), abdominal pain (6subjects), abdominal discomfort 
(2subjects), and flatulence (3 subjects).  Change of bowel habit, constipation, fecal volume 
increased, discolored feces, nausea, paraesthesia oral, and vomiting have each also been 
reported (1 subject each event).  All cases were mild in severity  with the exception of 
1 moderate TEAE each of abdominal pain, d ysphagia, and vomiting.
Skin and subcutaneous tissue disorders including, but not limited to rash, maculopapular 
rash, dermatitis acneiform, and ery thema of mild to severe intensit y were reported in the 
PF-06651600 cohorts and are summarized in Table 1below.  There were no skin and 
subcutaneous tissue disorders reported in the 5, 20, 50, 200, 400, and 800 single dose 
cohorts; nor were there any skin and subcutaneous tissue disorders reported in the 50 mgQD 
multiple dose cohort.
Table 1. Skin and Subcutaneous Tissue Disorder Occurrence
N= # of subjects
Adverse EventSAD
50mg
N=8SAD 
100mg
N=8MAD 
100mg 
BID
N=8MAD 
200mg 
QD
N=8SAD
400mg
N=16MAD 
400mg 
QD
N=24MAD 
200mg 
BID
N=8
A P A P A P A P A P A P A P
Acne 0 0 0 0 0 0 0 0 0 0 2*1*0 0
Derm atitis 
acneiform0 0 0 0 2*0 0 0 0 0 0 0 1*0
Dry Skin 0 1**0 0 0 0 0 0 0 0 2*1*0 0
Eczem a 0 0 0 0 0 0 0 0 0 0 0 1*0 0
Erythema 0 0 0 0 1*0 2*1*0 1*1*0 1**0
Rash 0 0 1*0 0 0 0 0 0 0 1*0 0 0
Rash macular 0 0 1*0 0 0 0 0 0 0 3*0 0 0
Rash 
maculopapular0 0 1**0 1**0 0 0 0 0 0 0 2
(1**/
1***)0
Rash pruritic 0 0 0 0 0 0 0 0 0 0 0 0 1**0
Seborrhoeic 
dermatitis0 0 0 0 1*0 0 0 0 0 0 0 0 0
Skin induration 0 0 0 0 0 0 0 0 0 0 0 0 0 1*
Abbreviations: A = active, P = placebo.
*-Mild ** -Moderate *** -Severe

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 23Three (3) serious adverse events (SAEs) were reported in the FIH trial. 
The first event was a cutaneous abscess on the left buttock during the 200 mg single dose 
period in a subject who entered the stud y with a pre -existing boil on the left buttock .This 
was assessed 19 days after the single dose was administered and was considered relat ed to 
the study  drug. The subject was discontinued from treatment.   The SAE criterion was met as 
the incision and drainage procedure was performed in a hospital setting.
The second SAE was a sacrococcy geal cy st/pilonidal sinus abscess during the 400 mg si ngle 
dose period.
  This was assessed 19 days after the single dose was administered and was 
considered related to the study  drug.  The SAE criterion was met as the incision and drainage 
procedure was performed in a hospital setting.
The third SAE was a var icella infection during the 400 mg QD MAD dose period.  The start 
date was 11days after the last dose and was considered related to the study drug .  The source 
of the infection is unknown; however, a second subject, who had a reactivation of varicella 
zoster, may  be the source as the subjects were confined during the same time.   The varicella 
infection resolved in 51 days. 
Please refer to the Investigator ’s Brochure for more details on the clinical safet y information 
with PF -
06651600.
1.5.2. Pharmacokinetics of PF-06651600 
The pharmacokinetic (PK) parameters from the 5, 20, 50, 100, 200, 400 and 800 mg single 
dose levels are summarized below in Table 2.  Ingeneral, PF-06651600 AUC infincreased in 
a dose related manner over the 5 to 800 mg dose range with a slightly  greater than 
proportional increase observed over the 200 mg to 400 mg dose range.
  Cmaxincreased with 
dose in an apparent dose proportional manner.
Table 2. Summary of Plasma PF -06651600 Pharmacokinet ic Parameters Following 
Single Oral Doses, Study B7981001
PF
-06651600 Param eter Summary Statisticsaby Treatment
Parameter, 
units5 mg 20 mg 50 mg 100 mg 200 mg 400 mg 800 mg
N, n 6,6 6,6 6,6 6,6 6,6 12,12 6,6
AUC inf, 
ng.hr/mL43.86 (26) 211.7 (39) 384.1 (47) 1085 (23) 2464 (42) 7824 (34) 16760 (18)
AUC last, 
ng.hr/mL42.42 (26) 209.3 (40) 382.6 (47) 1081 (23 ) 2461 (42) 7821 (34) 16760 (18)
Cmax, ng/mL 27.02 (29) 120.9 (54) 253. 3 (45) 647.7 (24) 1039 (40)) 2691 (26) 4992 (11)
Tmax, hr0.5 
(0.5-0.50.5 (0.5 -1) 0.5 (0.5 -1 0.5 (0.5 -0.6) 0.75 (0.5 -2) 1(0.5 -2) 1.5 (1 -2)
t½, hr1.20 
(0.107)1.2 (0.174) 1.13 (0.166) 1.48 (0. 176) 1.75 (0.434) 2.18 (0.337)2.48 
(0.460)
aGeom etric mean ( geometric %CV) for all except:  median (range) for Tmax; arithmetic me anSDfor t½.
N = Number of subjects in the treatment group and contributing to the mean; n= number of subjects where t½, 
AUC infwere determined .

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 24PF-06651600 was absorbed rapidl y following single doses of 5 mg to 200 mg with median 
Tmaxvalues 
0.750 hours, and more slowl y at the higher doses with a median T maxof 1.0 and 
1.5hours for the 400 mg and 800 mg doses, respectively .  Following attainment of C max, the 
disposition of 
PF-06651600 generall y showed a monophasic decline at the lower doses of 
5to 200mg (mean t½ of 1. 2to 1.8 hours) while a biphasic decline observed at doses of 
400to 800 mg (mean t½ of 2.2 to 2.5 hours).   An apparent trend toward longer t½ values at 
higher doses (400 and 800 mg) is probably  due to concentrations remaining above the
quantifiable limit for a longer period of time at the higher doses and defining a later terminal 
phase. 
The PK parameters following administration of 50, 200 and 400 QD and 100 mg and 
200mgBID for 14 days are summarized below in Table 3.
On Day 14 of multiple -dose administration, PF -
06651600 was absorbed rapidly  with median 
Tmaxvalues of 1 hour or less across the entire range of doses, from a total daily  dose of 50 mg 
(50mgQD) up to 400 mg (200 mg BI D or 400 mg QD).  
Followi ng attainment of C max, the 
disposition of 
PF-06651600 was consistent with that observed following single -dose 
administration, show ing a monophasic decline for the lowest doses and a biphasic decline 
following the 200 mg BID and 400 mg QD dosing regimens an d a mean terminal t½ of about 
approximatel y 1.3 to 2.3 hours.  In general, plasma PF-06651600 AUC and C maxincreased 
with dose across the 50 mg to 400 mg total daily  dose range in a dose related manner based 
on visual comparison of individual and dose normalized geometric mean C maxand AUC 
values.  Stead y-state generall y appears to have been reached b y Da y4 for the QD regimens 
and Day 6 for the BID regimens based on similar median trough (predose) concentrations on 
Days6, 8, 10, 12 and 14.
Table 3. Summary of Plasma and Urine PF -06651600 Pharmacokinetic Parameters 
Following Multiple Dose Administration for 14 days, Study B7981001
PF
-06651600 Param eter Summary Statisticsaby Treatment
Parameter, units 50mg (QD) 100mg (BID) 2 00 mg (QD) 400mg (QD) 200 mg (BID)
N, n 6, 6 4,4 5, 5 15, 14 5, 5
AUC, ng.hr/mL 540.1(38) 1984 (15 ) 4069 (22) 10040 (19) 5207 (24)
Cmax, ng/mL 315.2 (38) 663.0 (35) 1422 (28) 3136 (26) 1903 (27)
Tmax, hr 0.5 (0.5 -1) 0.75 (0.5 -2) 1 (0.5 -1) 1 (0.5 -2) 1 (0.5 - 1)
CL/F, L/ hr 92.56 (38) 50.43 (15) 49.14 (22) 39.85 (19) 30.41 (24)
t½, hr 1.3 (0.241) 2.11 (0.341) 1.84 (0.409) 2.16 (0.100) 2.27 (0.212)
Vz/F, L 170.6 (26) 151.4 (27) 128.0 (29) 126.1 (18) 125.3(18)
Ae% 4.09 (23) 6.46 (4) 5.47 (31) 6.46 (19 ) 7.04 (20)
CLr, mL/min 63.06 (28) 54.33 (12) 44.76 (38) 42.90 (18) 45.46 (17)
Geom etric mean ( geometric %CV) for all except:  median (range) for Tmax; arithmetic mean SDfor t½ ;
N =Number of subjects in the treatment group and contributing to the mea n; n= number of subjects where t½ 
was determined .
AUC,= Area under the concentration -time curve from zero to 24 hours (QD) or zero to 12 hours (BID) 
postdose at steady state; QD = Once daily; BID = Twice daily; C max=Peak plasma concentration; 
CL/F =apparent total body clearance; V z/F= apparent volume of distribution; Ae % = Percent of dose 
recovered unchanged in urine over the dosing interval ; CLr = Renal clearance.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 25Urinary  recovery  of PF -06651600 was low, with approximately  <8% of the dose recover ed 
unchanged in urine on Day 14 across all doses (geometric mean Ae % of 4.1% to 7.0%).   
Renal clearance ranged from 42.9 mL/min to 63.1 mL/min.
The relative bioavailability  (B7981003) of 50 mg PF- 06651600 tablets was compared to 
50mg oral suspension.  Th e ratio (90% CI) of adjusted geometric mean was 93.49% 
(87.8, 100) for AUC infand 90.4% (72.2, 113) for C maxunder fasted conditions.  When the 
50
mg tablets were administered under fed conditions, T maxwas slightly  delay ed with a 
median value of 1.0 hours , compared to a median T max0.5hours under fasted conditions.   For 
the 50 mg tablets fed vs. fasted, the ratio of adjusted geometric means for AUC infand C max
was 102% (95.2, 109) and 61.5% (48.5, 77.8), respectivel y.
1.6.Summary 
1.6.1. Study Rationale
This multice nter, placebo controlled study  will be the first determination of safet y and 
efficacy  of PF -06651600 in subjects with moderate to severe 
active RA who have had an 
inadequate response to methotrexate (up to approximately  50% of subjects may  also have 
had an inadequate response to 1 anti -TNFbiologic DMARD) .
The s ubject population in this study  ismethotrexate non -responders . These subjects could 
potentially  also have failed one TNF inhibitor.  The inclusion of subjects who have failed 
one TNFinhibitor i s d
riven by  the fact that anti -TNFtherapy  is widel y used in the US 
(which is planned to be one of the countries participating in this study ) in subjects who have 
failed methotrexate .  The deci sion to limit the number of TNF non responders in B7981006 
(up to 50% of study  subjects) is based on the American College of Rheumatology  (ACR )
recommendations to reserve anti
-TNFagents for RA subjects for whom prior methotrexate 
monotherap y led to an inadequate response, RA subjects with moderate disease activity and 
features of a poor prognosis, and for RA subjects with high disease activity, irrespective of 
prognostic features .15
In addition, although anti- TNFtherapy  is very  effective in controlling disease activity and 
slowing down radiological damage, prolonged response is only  seen in approximately  
60-70% of the subjects,7which indicates that there is an un-met need for RA subjects who 
fail anti -TNFtherap y.
An 8 week study  was determined of an appropriate duration to assess disease activity  and 
provide safet y information for PF -06651600 in subjects with RA .  SDAI  was selected as the 
primary  endpoint since this assessment 
is the best predictor for transformational efficacy  
defined in terms of 6 month SDAI  remission rate.
1.6.2. Dose Rationale
The dose selection strategy  was designed to balance pharmacolog y and safety for an 8 week 
study )in this subject population. 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 26 
 
 
 
 
The predicted PK parameters for PF-06651600 based on simulations using the global PK 
model are provided in Table 4.
Table 4. Summary of Predicted Steady State Plasma Pharmacokinetic and 
Pharmacodynamic Parameters Following Multiple Dose Administration of PF-06651600
Dose
mg QDCmax
ng/mLPredicted
MarginsaAUC tau
ng.hr/mLPredicted
MarginsaIP-10 
%CFB
200 1254 (2.1) 11 3712 (14) 14 42 (19)
AUC tau = Area under the concentration-time curve from zero to 24 hours 
postdose at steady state; C max= Peak plasma concentration; QD = Once daily; 
%CFB= percent change from baseline; human unbound fraction (fu) = 0.86; 1 ng/mL= 3.504 nM.
a.NOAEL-highest dose in dogs, 45 mg/kg/day; Week 8 mean male and female C
max(free) = 12,000 ng/mL; C max(total) = 14,634 ng/mL; AUC tau 
(free) = 44,100 ng•h/mL; AUC tau (total) = 53,780 ng•h/mL. dog (fu) = 0.82.
The predicted exposure during the treatment period at a dose of 200 mg QD for 8 weeks is 
projected to maintain 12- and 14-fold safety margins for C maxand AUC tau, respectively.  The 
selective inhibition of JAK3 will lead to modulation of -common chain cytokine pathways, 
such as IL-7, IL-15 and IL-21 which have been implicated in the pathophysiology of RA.  In 
lymphocytes, PF-06651600 inhibited JAK1/JAK3 dependent STAT5 and STAT3 phosphorylation by IL-15 and IL-21 respectively, with IC
50s of 56.5 ng/mL and 103 ng/mL, 
respectively.  All other pathways were inhibited at IC 50s >5708 ng/mL.  The predicted 
average percent IL-15 and IL-21 in-vitro signaling inhibition in human whole blood based on human PK are provided in Table 5.
Table 5. Summary of the Predicted Average Percent In Vitro Signaling Inhibition 
Based on Steady State PK from 200 mg PF-06651600
Cytokine Average Percent Signaling Inhibition
200 mg
IL-15 81
IL-21 71
Pharmacological modulation of the target can be inferred from the results. CCI
PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 271.6.3. Summary of Benefits and Risks
Overall, the safety profile observed during the Phase I program for PF-06651600 appears to 
be acceptable at dosages  administered orally. 
Additional information for this compound may be found in the single reference safety 
document (SRSD), which for this study is the Investigator’s Brochure. 
1.6.4. Additional Information
Banked biospecimens will be collected for the purpose of conducting research; specific uses 
are described in the Banked Biospecimens section.  Comparing the deoxyribonucleic acid (DNA), ribonucleic acid (RNA), protein, and metabolite variation patterns of subjects who respond well and those who respond poorly to treatment may help to better define the most appropriate group of subjects in which to target a given treatment.  Collecting biospecimens for exploratory pharmacogenomic/genomic/biomarker analyses and retaining them in the Biospecimen Banking System (BBS) make it possible to better understand the investigational product’s mechanism of action and to seek explanations for differences in, for example, exposure, tolerability, safety, and/or efficacy not anticipated prior to the beginning of the study. 
Banked biospecimens retained in the BBS also can be used in research on diseases of 
inflammation.
Providing these biospecimens is a required study activity for study sites and subjects, unless 
prohibited by local regulations or ethics committee (EC) decision. 
2. STUDY OBJECTIVES AND ENDPOINTS
Primary Objectives: Primary Endpoints:
To evaluate the efficacy of PF-06651600 
at 8 weeks in subjects with moderate to severe active RA.Change from baseline in simple disease activity index 
(SDAI) at Week 8.
Secondary Objectives: Secondary Endpoints:
To evaluate the s afety of PF-06651600. Safety and tolerability of PF-06651600 versus placebo; 
vital signs, laboratory tests, adverse events (AEs) 
including infections, and Serious Adverse Events 
(SAEs).
To assess other signs of clinical efficacy 
over 8 weeks.Change from baseline in SDAI at Weeks 1, 2, 4 and 6.
Change from baseline in SDAI low disease activity 
scale (LDAS) and remission rates at Week 4, Week 6 and Week 8 
Change from baseline in DAS28 LDAS and remission 
rates at Week 4, Week 6  and Week 8.
The following will also be calculated at Weeks 1, 2,4, 6 
and 8:CCI
PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 28Change from baseline in DAS28-3 (ESR), DAS28-3 
(CRP), DAS28 -4 (ESR), and DAS28-4 (CRP).
Change from baseline in hsCRP.
Change from baseline in the Tender/Painful and 
Swollen Joint Count (28).
Change from baseline in the Physician’s Global 
Assessment of Arthritis.
To assess the effect of PF-06651600 on 
patient reported outcome measurements.Change from baseline in the Patient’s Assessment of 
Arthritis Pain (VAS) and Patient’s Global Assessment 
of Arthritis (VAS) at Weeks 1, 2, 4, 6 and 8.
Change from baseline in the HAQ-DI at Weeks 1, 2, 4, 
6 and 8.
  
 
 
 
   
  
 
  
 
 
  
 
 
 
 CCI
PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 293.STUDY DESIGN
Figure 1.Study Design Schematic
Note:  N indicates the total number of completers.
This is a Phase 2a, 8 week randomized double -blind ,parallel group ,placebo controlled ,
multi-center study  to assess the efficacy  and safety  profile of PF -06651600 in seropositive 
subjects with moderate to severe active rheumatoid arthritis with an inadequate response to 
methotrexate (up to approximately  50% of subjects ma y also have had an inadequate 
response to 1 anti -TNFbiologic DMARD )
. 
Up to approximatel y 60subjects may berandomized globally  into the study to ensure at least 
approximatel y 50subjects complete 8 weeks of active dosing (assuming a dropout rate of 
approximatel y 15%).   Subjects will participate in this study  for approximately  17weeks.  
This includes an up to 5-week screening period, an 8 week treatment period, and a 4 week 
follow -up period. 
After an up to 5
week screening period, eligible subjects wil l be randomized to receive 
200mgQDof PF -06651600 or placebo (matching tablets for PF- 06651600 QD) every  day 
for 8weeks in a blinded fashion. 
Subjects will remain on stable background arthritis therap y, which must include methotrexate 
(supplemented wit h folic/folinic acid per local treatment guidelines).  Subjects additionally  
may continue stable doses of Nonsteroidal Anti -inflammatory  Drugs ( NSAIDs ), COX -
2 
inhibitors, allowed opioids (at doses  the potency  equivalent of 30 mg of 
orally -administered mo rphine ), acetaminophen/paracetamol for pain control (2.6grams per 
day), and/or low dose oral corticosteroids ( 10mg prednisone or equivalent per day ).  
Methotrexate must have been dosed orally  for at least 3 months, the dose must have been 
stable for at least 4 weeks before first dose of study  drug, and the dose must remain stable 
during the study .  Allowed methotrexate doses are 15 to 25 mg, inclusive, weekl y, unless 
there is documented (in the source documentation) intolerance to or toxicity from these
doses, in which case a dose between 10 and <15 mg, inclusive, may  be used. PF-06651600 , 2 00 mg QD, N = 308 Weeks
Dosing
5 Weeks 
Screening4 Weeks 
Follow UpPlacebo QD, N = 20

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 30Folic or folinic acid must be dosed per local standards of care stabl y for at least 4 weeks 
before first dose of stud y drug.  NSAIDs, COX -2 inhibitors, allowed opioids and/or low dose 
oral corticosteroids ( 10mg prednisone or equivalent per day ) must be dosed stably  for at 
least 4 weeks prior to first dose of study  drug (See Section 5.8).
4.SUBJECT ELIGIBILITY CRITERIA
This study  can fulfill its objectives only  if appropriate subjects are enrolled.  The following 
eligibility  criteria are designed to select subjects for whom participation in the study is 
considered appropriate.  All relevant medical and nonmedical conditi ons should be taken into 
consideration when deciding whether a particular subject is suitable for this protocol.
Subject eligibility  should be reviewed and documented by  an appropriate member of the 
investigator’s study  team before subjects are included i n the study .
4.1. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligibl e for enrollment into the 
study .
1.Evidence of a personally  signed and dated informed consent document indicating that 
the subject [or a legall y acceptab le representative ]has been informed of all pertinent 
aspects of the stud y.
2. Willing and able to comply  with scheduled visits, treatment plan, laboratory tests and 
other study  procedures .
3.Male and female subjects (including Women of Childbearing Potential ( WOCBP )) 
between the ages of 18 and 75 years, inclusive.   For subjects >70 years old, the site 
must discuss subject eligibility  with the study  team to ensure that these subjects are 
sufficiently  healthy  to participate .
4.Female subjects of childbearing poten tial must test negative for pregnancy at 
screening visit and baseline visit
.
5. Female subjects of nonchildbearing potential must meet at least 1 of the following 
criteria:
a.Achieved postmenopausal status, defined as follows: cessation of regular menses 
for at least 12 consecutive months with no alternative pathological or 
physiologica l cause and have a serum follicle -stimulating hormone (FSH) level 
confirming the postmenopausal state;
b.Have undergone a documented hy sterectomy  and/or bilateral oophorectomy ; 
c.Have medically  confirmed ovarian failure. 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 31All other female subjects (including female subjects with tubal ligations) are 
considered to be of childbearing potential.
6. Diagnosis of rheumatoid arthritis (RA) and meeting the 2010 American College of 
Rheumatology  (ACR)/European League Against Rheumatism (EUL AR) 
classification criteria (see Appendix 2) forRA with a Total Score 6/10.   The 
duration of time since diagnosis of RA should minimally  be sufficient to meet the 
definition of met hotrexate inadequate response (see criteria 10 below) .
7.Meets Class I, II or III of the ACR 1991 Revised Criteria for the classification of 
Global Functional Status in RA (see Appendix 2).
8.The subject has active disease at both Screening and Baseline, as defined by  both:

6 joints tender or painful on motion ;AND
  6 joints swollen;
and 
High sensitivity  Creactive protein (hsCRP) 7mg/L  at screening performed by  
the central laboratory .  Subjects who do not meet this entry  criter ion but satisfy  all 
other study  entry criteria may  have serum hs CRP concentration re -tested and, if 
the repeat hsCRP concentration is  7mg/L  prior to the baseline visit, will be 
eligible to enroll into the study  provided all other inclusion/exclusion crit eria are 
met.
9. Subjects must be seropositive (rheumatoid factor positive and/or anti -citrullinated 
protein antibody  positive ) at the screening visit.
10. Subjects must have been taking oral MTX for at least 3 months at an adequate dose to 
determine that the su bject had an inadequate response to MTX, defined, for the 
purpose of this study , by the investigator’s and subject’s opinions that the subject did 
not experience adequate benefit from methotrexate plus the presence of sufficient 
residual disease activity  to meet the entry  criteria.  Allowed methotrexate doses are 
15to 25 mg, inclusive, weekl y, unless there is documented (in the source 
documentation) intolerance to or toxicity  from these doses, in which case a dose 
between 10 and <15 mg, inclusive, may  be used (See Section 5.8). The dose must 
have been stable for at least 4 weeks before first dose of study
 drug, and the dose 
must remain stable during the study .  
Subjects should be on an adequa te and stable dose of folic acid (not less than 
5mg weekl y, unless higher doses would violate the local label) for at least 
4weeks prior to the first dose of investigational product or oral folinic acid 
(5mg once per week) supplementation for at least 4 weeks prior to the first dose 
of study  drug. Folic acid must be dosed per local standards of care stably  for at 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 32least 4 weeks before first study  dose and the dose must remain stable during the 
study .  In countries which do not have approved folic acid 1 mg or folinic acid 
5mg presentations, a regimen of folic acid of at least 5mg weekl y is acceptable.
11.Up to 50% of subjects may have received one approved TNF -inhibiting biologic 
agent administered in accordance with its labeling recommendations that w as 
inadequatel y effective and/or not tolerated .  For the purpose of this stud y, inadequate 
efficacy  is defined 
by the investigator’s and subject’s opinions that the subject did not 
experience adequate benefit from the anti -TNFinhibitor andthe presence o f 
sufficient residual disease activity  to meet the entry  criteria.   The anti-TNFinhibitor 
should have been discontinued for a minimum of the washout period defined as 
follows:
etanercept (Enbrel): 
4 weeks.
infliximab (Remicade), adalimumab (Humira), golimumab (Simponi) , 
certolizumab (Cimzia): 10weeks .
12.Subjects receiving non- prohibited medications (See Section 5.8) forany reason must 
be on a stable regimen, which is defined as not star ting a new drug or changing 
dosage within 7 days or 5 half-lives (whichever is longer) prior to first study  dose and  
the dose must remain stable during the study .
4.2.
Exclusion Criteria
Subjects with any  of the following characteristics/conditions will not be included in the 
study :
1. Investigat or site staff members directl y involved in the conduct of the study  and their 
family  members, site staff members otherwise supervised by  the i nvestigator, or 
subjects who are Pfizer employ ees, including their family  member s, directly  involved 
in the conduct of the study .
2. Participation in other studies involving investigational drug(s) within 30days or 
5half-lives (whichever is longer) prior to study  entry (screening visit ) and/or during 
study  participation .
3.Other acute or chronic medical or ps ychiatric condition including recent (within the 
past y ear) or active suicidal ideation or behavior or laboratory  abnormality  that may  
increase the risk associated with study  participation or investigational product 
administration or may interfere with the interpretation of study  results and, in the 
judgment of the investigator, would make the subject inappropriate for entry  into this 
study .

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 334.Any major illness/condition (s)or evidence of an unstable clinical condition (eg, renal, 
hepati c, hematologic, gastrointestinal, endocrine, pulmonary  or local active 
infection/infectious illness) that, in the investigator’s judgment will substantially  
increase the risk to the subject if he or she participates in the study .
5.Acute coronary  syndrome (e g, myocardial infarction, unstable angina pectoris) and 
any history  of cerebrovascular disease within 24 weeks before screening or in the 
period between the Screening Visit and the Baseline Visit.
6.Subjects with a known immunodeficiency disorder or a first degree relative with a 
hereditary  immunodeficiency .
7.Subjects with acute or active chronic dermatological disorders within 4 weeks prior to 
study  entry or in the period between the Screening Visit and the Baseline Visit .
8.Pregnant female subjects; breastfeeding female subjects; fertile male subjects and 
female subjects of childbearing potential who wish to become pregnant or who are 
unwilling or unable to use 2 highly  effective methods of contraception as outlined in 
this protocol for the duration of the stud y and for at least 28 days after the last dose of 
investigational product. 
9.History  of alcohol or drug abuse with less than 6
months of abstinence prior to the 
Baseline Visit .
10.Subjects with any  of the following acute or chronic infections or infections his tory:
a.Any infection requiring treatment within 2 weeks prior to the S creening Visit or 
in the period between the Screening Visit and the Baseline Visit .
b.Any infection requiring hospitalization, parenteral antimicrobial therapy  within 
60daysof the Baselin e Visit, or as otherwise judged to be an opportunistic 
infection or clinicall y significant by the investigator, within the past 6 months of 
the Baseline Visit .
c.Known active or history  of recurrent bacterial, viral, fungal, my cobacterial or 
other infections.
d.Recurrent (more than one episode) herpes zoster or disseminated (a single 
episode) herpes zoster or disseminated (a single episode) herpes simplex. 
e.Infected joint prosthesis at an y time with the prosthesis still in situ.
f.Subjects will be screened for H uman Immunodeficiency  Virus (HIV).  Subjects 
who test positive for HIV will be excluded from the study .

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 34g. Subjects will be screened for hepatitis B virus infection and will be excluded if 
positive for hepatitis B surface antigen (HBsAg).  Subjects with HBsAg negative 
testing but who test positive for hepatitis B core antibody  (HBcAb) must have 
further testing for hepatitis B surface antibody  (HBsAb).  If HBsAb is positive , 
the subject will be excluded from the stud y. 
h. Subjects will be screened for hepatitis C virus (HCV Ab).  Subjects with positive 
HCV Ab tests will be reflex tested for HCV ribonucleic acid (HCV RNA).   Only  
subjects with negative HCV Ab or HCV RNA will be allowed to enroll in the 
study .
11.
Subjects treated with prohibited medications will be excluded unless appropriate 
washout has been performed (See Section 5.8).
12.Any current evidence of untreated latent or active TB infection, evidence of currentl y 
active TB b y chest x -ray, residing with or frequent close contact with individual(s) 
with active TB.   Subjects who have a positive Mantoux (PPD) tuberculin skin test or 
a positive I nterferon Gamma Release Assay  during screening or within 12 weeks 
prior to 
screening .  The following are acce ptable assay s: QuantiFERON-TB Gold 
test (QFT- G), QuantiFERON-TB Gold I n-Tube test (QFT -GIT) and 
T-SPOT- TB test during screening or within 12 weeks prior to screening.
A positive Mantoux tuberculin skin test is defined as 5mm of induration (or a s 
defined b y countr y specific or local standards) at 48 -72hours without 
consideration of prior Bacillus Calmette -Guerin (BCG) vaccination.   
Documentation of the dose and product used for the Mantoux tuberculin test as 
well as the official test reading must be obtained and available in the subject’s 
source documentation.
An Interferon -Gamma Release Assay  (IGRA )
is preferred for subjects with a 
prior BCG vaccination, but may  be used for any  subject.   Documentation of 
IGRA product used and the test result mus t be in the subject’s source 
documentation. 
If the results of the IGRA are indeterminate, the test may  be repeated, and if a 
negative result is obtained, enrollment may  proceed.   A positive test on repeat is 
exclusionary .
13.Current routine household contact with children 
or any one else who have received 
varicella or oral polio or any  other live (attenuated) vaccine within 6 weeks of first 
study  dose, or during the course of the stud y(including the Follow U p period) .
14.Any live (attenuated) vaccines from 30 days prior to the B
aseline Visit and through 
the Follow U p Visit. 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 3515. Subjects who have been in contact with people with acute infections within 2 weeks 
prior to the S creening Visit or in the period between the Screening Visit and the 
Baseline Visit.
16.History  ofany lymphoproliferative disorder (such as Epstein -Barr Virus 
(EBV )
-related l ymphoproliferative disorder, as reported in some subjects on 
immunosuppressive drugs), history  of lymphoma, leukemia, my eloproliferative 
disorders, multiple my eloma, or signs and sy mptoms suggestive of current ly mphatic 
disease. 
17.Have a history  of a major organ transplant (eg, heart, lung, kidney  and liver) or 
hematopoietic stem cell/marrow transplant.  Skin grafts are allowed.
18.History  of severe allergic or anaphy lactoid reaction t o kinase inhibitors, or 
corticosteroid preparations.
19.Subjects with malignancy or history  of malignancy  (including but not limited to
lymphoma, leukemia, or ly mphoproliferative disease), with the exception of subjects 
with adequatel y treated or excised non -
metastatic basal cell or squamous cell cancer 
of the skin or cervical carcinoma in situ.
20.Pre-existing chronic autoimmune disease (eg, inflammatory  bowel disease, Systemic 
Lupus Erthematosus ( SLE), moderate tosevere atopic dermatitis) other than RA.   
Secon dary Sjogren’s - Syndrome associated with RA may  be included.
21.Major surgery  within 4 weeks of the S creening Visit or if scheduled to occur during 
the study , excluding diagnostic surgical procedures.
22.Previous treatment with total ly mphoid irradiation. 
23.Subje cts with any  condition possibly  affecting oral drug absorption (eg, gastrectom y, 
clinically -significant diabetic gastroenteropathy , or certain ty pes of bariatric surgery  
such as gastric b ypass).  Procedures such as gastric banding that simply  divide the 
stomach into separate chambers are notexclusionary .
24.Screening 12- lead ECG that demonstrates clinically  relevant abnormalities (eg, QTc 
>450 msec or a QRS interval >120 msec) which may  affect subject s’safet y or 
interpretation of stud y results.  I f QTc excee ds 450 msec, or QRS exceeds 120 msec, 
the ECG should be repeated two more times and the average of the three QTc or QRS 
values should be used to determine the subject’s eligibility .
25.Have current or recent history  of clinically  significant severe or progressive hearing 
loss or auditory  disease. Subjects with hearing aids will be allowed to enter the study  
provided their hearing impairment is considered controlled/clinically  stable. 
26.Subjects with an oral ortympanic temperature at the Baseline V isit of 38C or higher.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 3627.Presence of an y of the following laboratory abnormalities at the S creening Visit or 
within the 3 months prior to first study  dose:
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels 
1.5 times the upper limit of normal ( ULN).
Total bilirubin level 1.5times the UL N; subjects with a history  of Gilbert’s 
syndrome may  have a direct bilirubin measured and would be eligible for this 
study  provided the direct bilirubin is ULN and other liver function assessments 
are normal.
Hemoglobin level 90g/L ( 9.0g/dL).
Platelet count 100 x 109/L (100,000 cells/mm3) or 1000 x 109/L 
(1,000,000 cells/mm3).
White blood cell (WBC) count 3.0 x 109/L (3000 cells/mm3) or absolute 
neutrophil count (ANC) <1 500cells/mm3or absolute ly mphocy te count of 
<0.5 x
109/L (<500 cells/mm3).
Serum creatinine level 177mol/L  (2mg/dL).
Glycosylated hemoglobin (HbA1C) >10%.
28.In the opinion of the investigator or sponsor, have any  uncontrolled clinically  
significant laboratory  abnormality  that would affe ct interpretation of stud y data or the 
subject’s participation in the study .
29.Grade 3 or greater laboratory  abnormality  based on the Common Terminology  
Criteria for Adverse Events (CTCAE) version 4.03 toxicity  scale.
Screening laboratory  tests with abnormal results may  be repeated once to confirm abnormal 
results.  If results return to normal protocol acceptable limits within the 5-week screening 
period, the subject may  enter the study . 
Subjects who fail screening can be rescreened once .
4.3.Lifestyle Requirements 
It is recommended that subjects avoid consumption of grapefruit juice exceeding 8 ounces 
(~240 ml) total in a day  while in the study .
4.3.1. Contraception
In this stud y, fertile male subjects and female subjects who are of childbearing potential as 
applicable to the study  will receive PF-06651600, which has been associated with suspected 
teratogenicit y (based on the demonstrated nonclinical findings) .  Subjects who are, in the 
opinion of the investigator, sexuall y active and at risk for pregnancy with their partner(s) 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 37must agree to use 2 methods of highly  effective contraception throughout the study  and for at 
least 28 days after the last dose of PF -06651600.  The investigator or his or her designee, in 
consultation with the subject, will confirm that the subject has selected 2 appropriate methods 
of contraception for the individual subject and his/her partner(s) from the list of permitted 
contraception methods (see below) and will confirm that the subject has been instructed in 
their consistent and correct use.  At time points indicated in the Schedule of Activities, the 
investigator or designee will inform the subject of the need to use 2 highl y effective methods 
of contraception consistently  and correctly  and document the conversation, and the subject’s 
affirmation, in the subject’s chart.  In addition, the investigator or designee will instruct the 
subject to call immediately  if 1 or both of the selected contraception methods is discontinued 
or if pregnancy  is known or suspected in the subject or partner. 
Highly  effective methods of contraception are those that, alone or in combination, result in a 
failure rate of less than 1% per year when used consistently  and correctly  (ie, perfect use) and 
include the following:
Established use o f hormonal methods of contraception associated with inhibition of 
ovulation (eg, oral, inserted, injected, implanted, transdermal), provided the subject or 
male subject’s female partner plans to remain on the same treatment throughout the 
entire study  and has been using that hormonal contraceptive for an adequate period of 
time to ensure effectiveness. 
Correctly placed copper -containing intrauterine device (IUD).
Male condom or female condom used WI TH a separate spermicide product (ie, foam, 
gel, film, cre am, or suppository ).  For countries where spermicide is not available or 
condom plus spermicide is not accepted as highly  effective contraception, this option 
is not appropriate.
Male sterilization with absence of sperm in the postvasectomy  ejaculate. 
Bilateral tubal ligation/bilateral salpingectomy or bilateral tubal occlusive procedure 
(provided that occlusion has been confirmed in accordance with the device’s label).
All sexually  active male subjects must agree to prevent potential transfer to and exposure of 
partner(s) to drug through ejaculate b y using a condom consistently  and correctl y, beginning 
with the first dose of investigational product and continuing for at least 28 days after the last 
dose of investigational product.
4.4.Sponsor ’sQualified Medic
al Personnel
The contact information for the sponsor's appropriately qualified medical personnel for the 
study  is documented in the study  contact list located in thestudy manual . 
To facilitate access to appropriatel y qualified medical personnel on stud y
-related medical 
questions or problems, subjects are provided with a contact card.   The contact card contains, 
at a minimum, protocol and investigational product identifiers, subject study numbers, 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 38contact information for the investigat or site, and contact details for a contact center in the 
event that the investigat orsite staff cannot be reached to provide advice on a medical 
question or problem originating from another healthcare professional not involved in the 
subject’s participation in the study .The contact number can also be used by  investiga tor
staff if they  are seeking advice on medical questions or problems; however, it should be used
only in the event that the established communication pathway s between the investigator site 
and the study  team are not available. It is therefore intended to augment, but not replace, the 
established communication pathway s between the investigator site and the study  team for 
advice on medical questions or problems that may arise during the stud y.  The contact 
number is not intended for use by  the subject directly , and if a subject calls that number, he 
or she will be directed back to the investigator site.
If the subject has a medical emergency  and is unable to reach the investigator or the stud y 
staff, they  need to visit the Emergency  Room/Urgent Care or appropriate medical site for 
care b y a qualified health professional per local guidelines. 
5.STUDY TREATMENTS
For the purposes of this study , and per International Conference on Harmoni s ation ( ICH)
guidelines, investi gational product is defined as a pharmaceutical form of an active 
ingredient or placebo being tested or used as a reference /comparator in a clinical trial, 
including a product with a marketing authorization when used or assembled (formulated or 
packaged) i n a way  different from the approved form, or when used for an unapproved 
indication, or when used to gain further information about an approved use (ICH E6 1.33).
For this study , the investigational product is PF -06651600.  Investigational product will be
administered only  to subjects who have provided informed consent.  Once a subject’s 
participation in the study  has ended, investigational product will no longer be supplied to the 
subject by  the investigative site and/or sponsor. 
5.1.Allocation to Treatment
Allocation of subjects to treatment groups will proceed through the use of an interactive 
response technology  (IRT) system ( i
nteractive Web- based response [IWR]).  The site 
personnel (stud y coordinator or specified designee) will be required to enter or se lect 
information including but not limited to the user’s identification ( ID)and password, 
the 
protocol number ,andthe subject number. The site personnel will then be provided with a 
treatment assignment ,randomization number, and dispensable unit (DU) o r container number 
when investigational product is being supplied via the I RTsystem .  The IRT sy stem will 
provide a confirmation report containing the subject number , randomization number ,and DU 
or container number assigned. The confirmation report must be stored in the site’s files. 
The study -specific I RT reference manual will provide the contact information and further 
details on the use of the IRT system . 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 395.2.Breaking the Blind 
At the initiation of the study , the investigator site will be instructed on the method for 
breaking the blind.  The method will be an electronic process.  Blinding codes should be 
broken onl y in exceptional circumstances when knowledge of the actual treatment code is 
absolutely  essential for further management of the subject.  In vestigators are encouraged to 
discuss with a member of the study  team if they  believe that unblinding is necessary .  When 
the blinding code is broken, the reason must be fully documented and entered inthe case 
report form (CRF).
5.3.Subject Compliance
Subject compliance will be verified b y the accounting of investigational product at each visit. 
For self- administration of PF -06651600 at home, compliance will be captured and completed 
by the subject within a Subject Dosing Diary .  When investigational product is administered 
at the research facility , it will be administered under the supervision of study  personnel. 
Subjects will be directed to bring Subject Dosing Diary  and blister cards with any
 remaining 
study  drug to each visit for review.  Compliance with expected consumption of dispensed 
investigational product will be assessed by  comparing the expected number of doses to be 
taken to the number of doses returned (pill count) during an y given time period.
  Compliance 
will be documented in the source records. 
Non-compliance is defined as taking less than 80% or more than 120% of the allowed 
investigational product during the study  treatment period.
Subjects who are non -compliant will be counseled and the site will implement appropriate
measures to secure sub ject compliance, as appropriate to the site and reason for
non-compliance.   Subjects interrupting investigational product for more than 5days between 
study  visits are to be discussed with the medical monitor for possible discontinuation from 
the study .
Upon completion of each visit, the Subject Dosing Diary  should be collected from the subject 
at the site and stored in the site master file onl y.  The investigator has the discretion to 
withdraw an y subject from the study  for reasons of non
-compliance with t he dosing regimen.  
Inventory  control of all investigational product must be rigorously  maintained throughout the 
duration of the study  until all medication has been accounted for and/or returned to the 
sponsor.  Any  discrepancies noted between drug dispen sing records and drug inventory  must 
be reported to Pfizer.
5.4. Investigational Product Supplies
5.4.1. Dosage Form(s) and Packaging
Blinded PF -06651600 and its matching placebo will be provided as tablets in blister cards for 
oral administration.  The PF -06651600 50 mg tablets and their matching placebos will be 
supplied in separate blister cards and labeled according to local regulatory  requirements. 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 405.4.2. Preparation and Dispensing
The investigational product will be dispensed using an I RT drug management sy stem at each
visit from Week 0through Week 8.  Each dispensing visit will provide sufficient 
investigational product to complete dosing until the next scheduled dispensing visit.  Visit 
dates are calculated such that visit windows are not cumulative and are anchored on Day 0. 
Investigational product should be dispensed b y an appropriatel y qualified and experienced 
member of the stud y staff (eg, ph ysician, nurse, phy sician’s assistant, practitioner, or 
pharmacist) as allowed by  local, state, and institutional guidance , Onl y qualified personnel 
who are familiar with procedures that minimize undue exposure to their person and to the 
environment should undertake the preparation, handling, and safe disposal of agents.
The subject should be instructed to maintain the produc t in the blister cards provided 
throughout the course of dosing and return the blister cards to the site at the next study  visit. 
5.5.Administration
Subjects will receive PF -06651600 tablets and matching placebo for oral administration in 
blister packs.  Subj ects will be dispensed blister cards and given clear dosing instructions. 
Investigational product tablets will be administered to the subject in the clinic on the morning 
of clinic visits and all other dosing will be performed by  the subject outside of th
e clinic.   
Subjects will record their study  drug dosing information within a Subject Dosing Diary  
which should be brought to each clinic visit.
Sites will be trained on how subjects should take tablets at home through the study  or IP
manual and/or other ve hicle(s).  Sites are responsible for communicating this information to 
the subject . 
If a dose is missed and the interval to the next dose is less than 6 hours, the missed dose 
should not be administered.   At the baseline visit, (Visit 2) the first dose of investigational 
product will be taken in the clinic.  Additionally , at Weeks 1, 2, 4, 6 and 8 subjects should 
take their dose for that day in the clinic.   All other doses will be taken by  the subject outside 
of the clinic.
The investigational product may be administered with or without food. Subjects will 
swallow the investigational product whole, and will not manipulate or chew the 
investigational product prior to swallowing with a glass of water . 
Subjects who experience AEs that require treatment may  have their study  drug temporaril y 
discontinued during treatment at the investigator’s discretion.  Subjects interrupting 
investiga tional product for more than 5 days are to be discussed with the medical monitor for 
possible discontinuation from the study .
Temporary  discontinuation of study  drug should be recorded in the CRF.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 415.6. Investigational Product Storage 
The investigator o r an approved representative, eg, pharmacist, will ensure that all 
investigational products are stored in a secured area with controlled access under required 
storage conditions and in accordance with applicable regulatory  requirements .
Investigational product sshould be stored in their original container sand in accordance with 
the label s. 
Any storage conditions stated in the SRSD willbe superseded b y the storage conditions 
stated on the product label.
Site sy stems must be capable of measuring and documenting (for example, via a log), at a 
minimum, daily  minimum and maximum temperatures for all site storage locations (as 
applicable, inc luding frozen, refrigerated ,and/or room -temperature products).  This should 
be captured from the time of investigational product receipt throughout the study .  Even for 
continuous- monitoring sy stems, a log or site procedure that ensures active evaluation for 
excursions should be available .  The intent is to ensure that the minimum and maximum 
temperature is checked each business day  to confirm that no excursion occurred since the last 
evaluation and to provide the site with the capability  to store or view the minimum/maximum 
temperature for all non
-working day s upon return to normal operations.  The operation of the 
temperature monitoring device and storage unit (for example, refrigerator), as applicable, 
should be regularl y inspected to ensure they are mai ntained in working order. 
Any excursions from the product label storage conditions should be reported to Pfizer upon 
discovery . The site should actively  pursue options for returning the product to the storage 
conditions described in the labeling , as soon as possible.  Deviations from the storage 
requirements, including any  actions taken, must be documented and reported to Pfizer . 
Once an excursion is identified, the investigational product must be quarantined and not used 
until Pfizer provides permission to use the investigational product.  It will not be considered a 
protocol deviation if Pfizer approves the use of the investigational product after the 
temperature excursion. Use of the investigational product prior to Pfizer approval will be 
considered a protocol deviation. Specific details regarding information the site should report 
for each excursion will be provided to the site.
Receipt of materials, door opening and closing, and other routine handling operations where 
the products are briefl y out o f thetemperature range described in the labeling are not 
considered excursions.
Site staff will instruct subjects on the proper storage requirements for take home 
investigational products . 
5.7. Investigational Product Accountability 
The investiga torsite mus t maintain adequate records documenting the receipt, use, loss, or 
other disposition of the investigational product supplies.   All investigational products will be 
accounted for using a drug accountabilit y form/record.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 42All blister cards of study  drug must be returned to the investigator by  the subject at every  
visit and at the end of the trial.
5.7.1. Destruction of Investigational Product Supplies 
Returned investigational product can be destro yed only  after the sponsor monitor has verified 
the accuracy  of the dispensing and inventory  record. 
The sponsor or designee will provide guidance on the destruction of un used investigational 
product (eg, at the site). If destruction is authorized to take place at the investigator site, the 
investigator must ensure that t he materials are destroy ed in compliance with applicable 
environmental regulations, institutional policy , and any  special instructions provided by  
Pfizer ,and all destruction must be adequatel y documented.
5.8.Background and Concomitant Treatment(s)
All concom itant medication(s) and treatment(s) administered/taken during the study must be 
recorded with indication, daily  dose, and start and stop dates of administration. 
All subjects will be questioned about concomitant medication at each site visit. 
Medication s that are taken after informed consent is obtained, but before the first dose of 
investigational product
,will be documented as prior medications.   Medications taken after 
the first dose of 
investigational product has been administered will be documented as 
concomitant medications. 
5.8.1. Permitted Background Arthritis Therapy
Methotrexate (MTX) (Required Background RA T reatment).
Subjects will continue on their pre -study  dose of MTX (supplemented with folic/folinic 
acid). Subjects must have been taking oral MTX for at least 3 months at an adequate dose to 
determine that the subject had an inadequate response to MTX, defined, for the purpose of 
this study , by the investigator’s and subject’s opinions that the subject did not experience 
adequate benefit from MTX plus the presence of sufficient residual disease activity  to meet 
the entry  criteria.  The dose must have been stable for at least 4 weeks before first dose of 
study  drug, and the dose must remain stable during the study .  Allowed MTX doses are 15 to 
25
mg, inclusive, weekl y, unless there is documented (in the source documentation) 
intolerance to or toxicit y from these doses, in which case a dose between 10 and <15 mg, 
inclusive, may  be used.
Other background RA Treatments
The following concomitant medicat ions may  be continued during the study  as background 
RA treatments, provided the dosage(s) do not change for the entire period from Screening 
through Discharge from the study (except for Rescue Medication. See Section 5.9) and have 
been stable f or the stip ulated interval before Randomization and dosing with the 
investigational product.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 43Anti- malarials (eg, chloroquine,hy droxy chloroquine) .
Nonsteroidal Anti -inflammatory  Drugs (NSAIDs), selective C ycloox ygenase -2 
inhibitors ("COX -2 inhibitors") at a stable dos ein accordance with local 
label/standard of care beginning at least 4 weeks prior to first study  dose.
Opioids at doses the potency  equivalent of 30 mg of orall y-administered morphine 
at a stable dose beginning at least 4 weeks prior to first study  dose (See 
Appendix 11).
Acetaminophen/paracetamol at doses 2.6grams per day  
Low dose oral corticosteroids ( 10mg prednisone or equivalent per day ) at a stable 
dose beginning at least 4 weeks prior to first study dose (See Appendix 10).
Subjects should be on an adequate and stable dose of folic acid (not less than 5 mg 
weekl y, unless higher doses would violate the local label) for at least 4 weeks prior to 
the first dose of 
investigational product or oral folinic acid ( 5mg once per week) 
supplementation for at least 4 weeks prior to the first dose of study  drug. Folic acid 
must be dosed per local standards of care stably  for at least 4 weeks before first study  
dose and the dose must remain stable du ring the study .  In countries which do not 
have approved folic acid 1 mg or folinic acid 5 mg presentations, a regimen of folic 
acid of at least 5mg weekly  is acceptable .
Other Permitted Concomitant Medications
A subject who is receiving an allowed conco mitant medication for any  reason must be on a 
locally -approved medication and dose that is considered standard -of-care for the treated 
indication and be documented in the case report form with indication, daily  dose, and start 
and stop dates of administrat ion.
It is recommended that subjects receiving non -prohibited concomitant medications, vitamins, 
and dietary  supplements must be on a stable regimen , which is defined as not starting a new 
drug or changing dosage within 7 days or 5 half-lives (whichever is longer) prior to first dose 
of investigational product and the dose must remain stable during the study.   
5.8.2. Prohibited Background Arthritis Therapy 
Disease Modify ing Antirheumatic Drugs (DMARDs)
Subjects who have received the following treatment regimens are eligible to 
participate in the study, providing the following discontinuation periods are observed 
prior to the first dose of investigational product . (Biosimilars of the below agents 
should be considered the same as the originators) .

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 44Biologics
TNF in hibitors
Up to 50% of subjects may  have received one approved TNF -inhibiting biologic 
agent administered in accordance with its labeling recommendations that was 
inadequatel y effective and/or not tolerated . For the purpose of this stud y, 
inadequate effic acy is defined by the investigator’s and subject’s opinions that the 
subject did not experience adequate benefit from the anti- TNFand the presence 
of sufficient residual disease activit y to meet the entry criteria.   The anti -TNF
should have been discont inued for a minimum of the washout period defined as 
follows:27
etanercept (Enbrel): 
4 weeks.
infliximab (Remicade), adalimumab (Humira), golimumab (Simponi), 
certolizumab (Cimzia): 10weeks .
Other Biologi c Agents /DMARDs
Subjects who have previously  been treated with other, non- TNFinhibiting 
biologic DMARDs (including, abatacept (Orencia), tocilizumab (Actemra), 
anakinra (Kineret), rituximab (Rituxan) or other selective B 
lymphocy te-depleting agents ( both marketed and investigational)) or other 
lymphocy te-depleting agents/therapies (such as CamPath[alemtuzab], alky lating 
agents [eg, cy clophosphamide or chlorambucil], total ly mphoid irradiation) are 
excluded from participation in the current stud y.
Subjects who have been previously  treated with tofacitinib (Xeljanz) should 
have a washout treatment of 3 months prior to screening.
Intra -articular, intravenous or intramuscular corticosteroids, DMARDs including 
methotrexate and biologic response modifiers are not allowed during this study . 
Other RADrugs
The following drugs are excluded during the study  and for the prescribed washout period 
prior to the start of the study :
Auranofin (oral gold), aurothioglucose (injectable gold), aurothiomalate (injectabl e 
gold) must be discontinued for 8 weeks prior to the first dose of the investigational 
product .
Sulfasalazine, d -penicillamine, bucillamine, mizoribin, azathioprine, cy closporine, 
tacrolimus, and staph ylococcal protein A immuno -absorbant pheresis columns 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 45(eg,PROSORBAdevice/column) must be discontinued for 4 weeks prior to the first 
dose of investigational product .
Subjects on Leflunomide (Arava) must undergo the following drug elimination 
procedure at least 4 weeks prior to the first dose of investigat ional product :
Cholesty ramine at a dosage of 8 grams three times daily  for at least 11 days, or 
activated charcoal at a dosage of 50 grams 4 times a day  for at least 11 days to 
achieve non -detectable plasma levels (less than 0.02 mg/L  or 0.02g/mL) after 
stopping treatment with Arava22
,23Verify plasma levels less than 0.02 mg/L  
(0.02g/mL) by  two separate tests at least 14 days apart.   If plasma levels are 
higher than 0.02 mg/L , additional cholesty ramine treatment should be considered. 
Tetracy clines and minocy cline, unless prescribed for the treatment of acne or other 
dermatologic disorders, must be discontinued for 4 weeks prior to the first dose of 
investigatio nal product .
Other Prohibited Concomitant Medications
Interferon therap y within 8 weeks prior to the B aseline Visit and through the 
Follow up Visit.
Lym phocy te-depleting agents/therapies .
Leukocy te apheresis including selective ly mphocy te, monocy te, or gra nulocy te 
apheresis, or plasma exchange within 6 months of baseline and through the Follow up 
Visit. 
Other marketed immunosuppressants or biologics with immunomodulatory  properties 
within 3 months prior to the Baseline Visit and through the Follow up Visit .
Use of immunosupressants used in transplant ation (eg, my cophenolate mofetil, 
cyclosporine, rapam ycin, or tacrolimus) within 30 days prior to the Baseline Visit and 
through the Follow up Visit.
Any live (attenuated) vaccines from 30 days prior to the B aselineVisit and through 
the Follow up Visit.
No investigational compounds, other than PF -06651600, may  be taken during 
participation in this study .
Herbal medications with pharmaceutical properties must be discontinued at least 
4weeks before the first dos e of investigational product.
Subjects receiving prohibited concomitant medications, including moderate to potent 
CYP3A inducers or inhibitors (See Appendix 4) in the time periods described below:

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 46For moderate to potent CYP3A inducers, within 28 days or 5 half-lives, 
whichever is longer, prior to the Baseline Visit .
For moderate to potent CYP3A inhibitors, within 7 days or 5 half-lives, 
whichever is longer, prior to the Baseline Visit .
Subjects who are treated with any  prohibite d medication during the course of the study  will 
be discontinued. 
5.9.Rescue Medication
Rescue therap y for RA is not permitted except for transient (up to 10consecutive day s) 
addition or increased dose of acetaminophen/paracetamol (dosed no more than 2.6 grams per 
day) or an opioid (not exceeding the potency  equivalent of 30 mg of orall y
-administered 
morphine) If a subject is alread y taking stable background doses of 
acetaminophen/paracetamol, s/he may  increase the dose up to 2.6 grams per day  for up to 
10
consecutive day s for rescue purposes.  Subjects who require rescue for more than 
10consecutive days should be discontinued from the trial.   Acetaminophen/paracetamol 
may be taken for up to 5 days/week for headache, fever, or other acute, non -arthritis pain , 
provided the total dose (including background dose) does not exceed 2.6 grams per 
day. 
Subjects should not be dosed with rescue treatments during the 24 hours prior to interval 
study  visits and 7 days prior to the last day  of the active dosing period (W eek8).  
(Note: baseline stable doses of acetaminophen/ paracetamol or opioids should NOT be 
discontinued in advance of study  visits) ( See Appendix 11).
6.
STUDY PROCEDURES 
Visits should occur when scheduled, within the time wind ow indicated in the Schedule of 
Activities.  Written informed consent must be obtained prior to performing any  
protocol -specific procedures, including washout of prohibited medications. On study  drug 
dosing day s, PtGA and PAAP VAS measures and HAQ- DI questionnaires, should be 
performed prior to an y other assessments.  Assessments including joint counts, phy sician 
questionnaire, and pre -dose blood collections are to be performed prior to dosing unless 
otherwise stated.
Where possible the following order of activities should be followed during the clinic visits
1. Patient’s Assessment of Arthritis Pain (VAS) and Patient Global Assessment of Arthritis 
(VAS)
2. ECGs
3.Vital signs
4.Physician’s Global Assessment (PhGA) of Arthritis (Phy sician’s as sessment should be 
performed without knowledge of patient reported VAS assessments)

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 475.Blood and Urine Sample Collection 
6.Investigational Product Dosing
6.1.Screening
For screening procedures, see Schedule of Activities and ASSESSMENTS section.
6.2.Treatment Period
For treatment period procedures, see Schedule of Activities and ASSESSMENTS section.
6.3.Follow -up/End of Study
For follow -up and end of study  procedures, see Schedule of Activities and ASSESSMENTS
section.
6.4.Subject Withdrawal/Early Withdrawal
Subjects may withdraw from the study  at any  time at their own request, or they  may  be 
withdrawn at an y time at the discre tion of the investigator or sponsor for safety  (see also the 
Withdrawal From the Study  Due to Adverse Events section) or behavioral reasons, or the 
inability  of the subject to comply  with the protocol -required schedule o f study  visits or 
procedures at a given study  site (See Schedule of Activities for procedures to be followed at 
the Earl y Withdrawal Visit) . Subjects who require rescue medication for more than 
10consecutive day s should be discont inued from the trial. (See Section 5.9)
Subjects who are discontinue d from study  treatment will enter into the Follow -up Period 
with the 
follow -up vi sit occurring 1 week after the last dose wh enever possible and 
protocol specified follow- up procedures should be performed . 
See Appendix 4for Guidelines for Monitoring and Discontinuations.  The Early Withdrawal
Visit applies to subjects who are randomized, received a t least one dosing and then are 
prematurel y withdrawn from the study treatment.
Subjects who withdraw from the study  may  be replaced at the discretion of the investigator 
upon consultation with the sponsor. 
6.4.1. Withdrawal of Consent
If the subject withdraws f rom the study , and also withdraws consent for disclosure of future 
information, no further evaluations should be performed, and no additional data should be 
collected.  The sponsor may  retain and continue to use any  data collected before such 
withdrawal of consent.
Subjects should notify  the investigator in writing of the decision to withdraw consent from 
future follow -up, whenever possible.  The withdrawal of consent should be explained in 
detail in the medical records by  the investigator, as to whether the withdrawal is only  from 
further receipt of investigational product or also from study  procedures and/or post -treatment 
study  follow -up, and entered on the appropriate CRF page.  I n the event that vital status 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 48(whether the subject is alive or dead) is being assessed , publicly  available information should 
be used to determine vital status only  as appropriately  directed in accordance with local law.
6.4.2. Lost to 
Follow -up 
Lost to follow -up is defined by  the inability  to reach the subject after a minimum of 2 phone 
calls (documented in the source documents), faxes, or e
-mails as well as lack of response b y 
the subject to 1 registered mail letter. 
If a subject does not return for a scheduled visit, every  effort should be made to contact the 
subject.  All attempts to contact the subject and information received during contact attempts 
must be documented in the subject’s medical record.  In an y circumstance, every  effort 
should be made to document subject outcome, if possible.  The investigator should inquire 
about t he reason for withdrawal, request that the subject return all unused investigational 
product(s), request that the subject return for a final visit, if applicable, and follow up with 
the subject regarding an
y unresolved adverse events (AEs).
If it is determ ined that the subject has died, the site will use locally  permissible methods to 
obtain the date and cause of death.  If, after all attempts, the subject remains lost to 
follow -up, then the last -known -alive date as determined by  the investigator should be 
reported and documented in the subject’s medical records.
7.ASSESSMENTS
Every  effort should be made to ensure that the protocol -required tests and procedures are 
completed as described. However ,it is anticipated that from time to time there may  be 
circumst ances outside of the control of the investigator that may  make it unfeasible to 
perform the test. In these cases the investigator will take all steps necessar y to ensure the 
safet y and well -being of the subject. When a protocol -required test cannot be pe rformed, the 
investigator will document the reason for this and any corrective and preventive actions that 
heor she has taken to ensure that normal processes are adhered to as soon as possible. The 
study  team will be informed of these incidents in a time ly manner .
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .
7.1.Efficacy Assessments
7.1.1. American Colleg e of Rheumatology (ACR) Assessments 
The specific components of the ACR Assessments (ACR Core Dataset) that will be used in 
this study  are:
1.Tender/Painful Joint count (TJC) (68).
2.
Swollen Joint Count (SJC) (66).
3.Patient’s Assessment of Arthritis Pain.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 494.Patie nt’s Global Assessment of Arthritis.
5.Physician’s Global Assessment of Arthritis.
6. C- Reactive Protein (CRP), measured b y high sensitivity  methodology  (hsCRP).
7.Erythrocy te Sedimentation Rate (ESR)
8.Health Assessment Questionnaire –Disability  Index (HAQ -DI).
Components of the ACR Core Dataset will be collected at the visits indicated in the Schedule 
of Activities.
7.1.2. Tender/Painful Joint Count (68)
Sixty -eight (68) joints will be assessed b y a joint assessor to determine the number of joi nts 
that are considered tender or painful.  The response to pressure/motion on each joint will be 
assessed using the following scale: Present/Absent/Not Done/Not Applicable (to be used for 
artificial or missing joints).  Artificial joints will not be asses sed.
The 68 joints to be assessed are:
Upper Bod y: temporomandibular, sternoclavicular, acromioclavicular;
Upper Extremit y: shoulder, elbow, wrist (includes radiocarpal, carpal and 
carpometacarpal considered as one unit), metacarpophalangeals (MCP I, II, I II, IV, 
V), thumb interphalangeal (I P), proximal interphalangeals (PIP II, III, IV, V), distal 
interphalangeals (DIP II, III, IV, V);
Lower Extremity : hip, knee, ankle, tarsus (includes subtalar, transverse tarsal and 
tarsometatarsal considered as one unit ), metatarsophalangeals (MTP I, II, III, IV, V), 
great toe interphalangeal (I P), proximal and distal interphalangeals combined (PI P II, 
III, IV, V).
7.1.3. Swollen Joint Count (66)
The joint assessor will also assess joints for swelling using the following scale:
Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints). 
Sixty -six (66) joints will be assessed for swelling, the same as those listed above for 
tenderness/pain, except that the right and left hip joints are not included in t he swollen joint 
count.  Artificial joints will not be assessed.   Phy sician assessment should be performed 
without the knowledge of patient reported outcome measures.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 507.1.3.1. Tender and Swollen Joint Counts (28)
The twent y-eight tender/painful joint count includes the following joints: shoulders, elbows, 
wrists, metacarpophalangeal joints (MCP), proximal interphalangeal joints (PI P), and knees.  
Artificial joints will not be assessed.   This count will be calculated b y Pfizer from the 
68tender/painful joint count a ssessed b y the joint assessor as 
described in Section 7.1.2.
The twent y
-eight swollen joint count measurement will include the same joints as described 
above for 28 tender/painful joint count, and will be calculated by Pfizer from the 66 swollen 
joint count assessed for swelling by  the joint assessor as described in Section 7.1.3.  Artificial 
joints will not be assessed.
  Phy sician assessment should be performed without the 
knowledge of patient reported outcome measures.
7.1.4.
Patient’s Assessment of Arthritis Pain (PAAP)
Subjects will assess the severit y of their arthritis pain using a 100 mm visual analog scale 
(VAS) b y placing a mark o n the scale between 0 (no pain) and 100 (most severe pain), which 
corresponds to the magnitude of their pain (See 
Appendix 7).  This assessment must be 
performed early  in the clinic visit and before the subject has extensive co ntact with site 
personnel and/or investigator
(and ideally  should be performed before the TJC and SJC 
measurements) and prior to dosing .
7.1.4.1. Patient’s Global Assessment (PtGA) of Arthritis
Subjects will answer the following question, “Considering all the way s your arthritis affects 
you, how are you feeling today ?”  The subject ’s response will be recorded using a 100 mm 
visual analog scale ( VAS) (See Appendix 8).  This assessment must be performed early  in 
the clinic visit and before the subject has extensive contact with site personnel and/or 
investigator and prior to dosing.
7.1.4.2. Physician’s Global Assessment (PhGA) of Arthritis
The investigator will assess how the subject ’s overall arthritis appears at the time of the visit.  
This is an evaluation based on the subject ’s disease signs, functional capacity  and ph ysical 
examination, and should be independent of the Patient’s Global Assessment of Arthritis.  The 
investigator’s response will be recorded using a 100 mm visual analog scale (VAS ) 
(See Appendix 9).  Physician assessment should be performed without the knowledge of 
patient reported outcome measures.
7.1.4.3. High Sensitivity C- Reactive Protein (CRP)
Samples for anal ysis of high sensitivity  CRP (hsCRP) will be collected at the visits specified 
in the Schedule of Activities.  The samples will be shipped to and anal yzed by  a central 
laboratory .  After randomization, the investigator and Pfizer study personnel directl y 
involved in the conduct of the trial will be kept blinded of the results of this test.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 517.1.4.4. Erythrocyte Sedimentation Rate (ESR)
Samples for anal ysis of ESR will be collected at the visits specified in the Schedule of 
Activities.  ESR will be analy zed by  a locallaboratory  using the Westergren method.  The 
results from the local laboratory  will be captured in a central database. 
7.1.4.5. Health Assessment Questionnaire – Disability Index (HAQ- DI) 
The HAQ -DI assesses the degree of difficulty  a subject has experienced during the past week 
in 8domains of daily  living activities: dressing and grooming, arising, eating, walking, 
hygiene, reach, grip, and other activities.   Each activity  category  consists of 2 - 3items.  For 
each question in the questionnaire, the level of difficulty  is scored from 0 to 3 with 
0representing “ without any difficulty ,” 1 as “some difficult y,” 2 as “much difficulty,” and 
3as “unable to do.”  An y activity  that requires assistance from another individual or requires 
the use of an assistive devi ce adjusts to a minimum score of 2 to represent a more limited 
functional status.   This questionnaire must be performed early  in the clinic visit and before 
the subject has extensive contact with site personnel and/or investigator.   The form should 
then be checked b y the site staff for completeness.  A cop y of the questionnaire can be found 
in Appendix 13.  This must be performed early  in the clinic visit and before the subject has
extensive contact with site personnel and/or in vestigator and prior to dosing .
7.1.5. Composite Efficacy Assessments Derived from the ACR Core Dataset
Composite endpoints in this study  will be calculated by  Pfizer using individual components.
7.1.5.1. Simple Disease Activity Index (SDAI) Assessment
The SDAI is a conti nuous composite measure derived components of the ACR Core Dataset.   
The SDAI will be calculated using the following formula:
SDAI  = TJC (using 28 joints) + SJC (using 28 joints) + PtGA (0
–10cm scale) + PhGA 
(0-10cm scale) + and hsCRP (mg/dL ).1
7.1.5.2. ACR Responder Analysis
The American College of Rheumatology ’s definition for calculating improvement in RA 
(ACR20) is calculated as a 20% improvement in tender and swollen joint counts and 
20% improvement in 3 of the 5 remaining ACR- core set measures: patient ’sand phy sician ’s
global assessments, pain, disability , and an acute -phase reactant.  Similarly, ACR50 and 
ACR70 are calculated with the respective percent improvement.  Components of the ACR 
Responder Index will be collected as indicated in the Schedule of Activities.
7.1.6. Disease Activity Score (DAS) Assessments
The Disease Activity  Score (DAS) assessment is a continuous composite measure derived 
using differential weighting given to each compone
nt.  DAS28 is a measure based on 
28tender and swollen joint counts.  DAS28 may  be calculated with 3 components (not 
including assessment of an acute phase reactant) (DAS28 -3) or 4 components 
(DAS28 -4 = DAS28 -3 + either ESR or CRP).   The formulae for calcu lation of DAS28 -4 
(CRP) and DAS28 -4 (ESR) are presented in Appendix 6.  Components of DAS 28-3 (CRP) , 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 52DAS28-3 (ESR), DAS28-4 (CRP), and DAS28- 4 (ESR) will be collected as indicated in the 
Schedule of Acti vities.
The components of the DAS 28 arthritis assessment include:
Tender/Painful Joint Count (28).
Swollen Joint Count (28).
CRP or ESR.
Patient’s Global Assessment of Arthritis.
7.2.Safety and other Assessments
Safety  will be assessed by the spontaneous re porting of AEs, phy sical examinations, ECGs, 
and clinical laboratory  results in all subjects who received at least 1 dose of investigational 
product .  Investigators and Pfizer c linician /medical monitor will review individual subject 
data throughout the con duct of the trial to ensure subjects’ well- being.
7.2.1. Clinical Safety and Other Laboratory Tests
The following laboratory tests will be performed at times defined in the Schedule of 
Activities
.  Laboratory tests may be repeated once du ring the screening period; the last value 
will be used to determine eligibility .  Unscheduled clinical labs may  be obtained at an y time 
during the study  to assess any  perceived safet y concerns.
Table 6. Safety and other Laboratory T ests
Hematology Blood Chemistry Urinalysis Other
Hemoglobin
Hematocrit
RBC count
Platelet count
WBC count
Total neutrophils (Abs and %)
Eosinophils (Abs and %)
Basophils (Abs and %)
Lymphocytes (Abs and %)
Monocytes (Abs and %)
Reticulocyte count (Abs an d %)
PT/INR/PTTBUN/Urea & Creatinine
Glucose (fasting)
Calcium
Sodium
Potassium
Chloride
Total CO 2(Bicarbonate)
AST, ALT
Total bilirubin
Direct bilirubing
Alkaline phosphatase
Uric acid
Albumin
Total protein
Lipid profiles c
Creatine kinase (CK)
CK frac tionationhpH
Glucose 
Protein 
Blood 
Ketones
Nitrites
Leukocyte 
esterase
Urobilinogen
Urine bilirubin
MicroscopydFSHa
Pregnancy Testsb
HbA1c
HIVi, HBsAg, HBc Ab , HBsA b 
and HCVAb , HCV RNA
IGRAk
Viral surveil lancee
Ig subtypes
Herpitiform rash evaluation 
(HSV and HZV swab)
Skin biopsies/swabsf
IP-10j
Anti CCP antibodiesj
Rheumatoid Factorj
C-Reactive Protein ( hsCRP)j
Tcell, B cell and NK cell
subsets
ESR
Exploratory samples (serum, 
plasma, RNA , DNA )
a.In females who are amenorrheic for at least 12 consecutive months to confirm post -menopausal status . 
b.Pregnancy tests (serum/urine) for w omen of childbearing potential .Serum  pregnancy test must be 
performed at screening.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 53c.Lipid profile panel will include total cholesterol, low -density lipoprotein (LDL), high -density lipoprotein 
(HDL), and triglycerides.  A minimum of 8 -hour fasting is required for lipid profile evaluation at Day 1, 
Week 4, W eek8, and EOS. 
d.Only if urine dipstick is positive for blood, protein, nitrites or leukocyte esterase.
e.Blood sample will be collected for potential exploratory viral load analyses including but not limited to 
CMV, EBV, HSV1, HSV2, and VZV, if applicable .
f.When required in cases of skin rash adverse events .Skin swab sfor herpetiform rash and s kin swab for 
potential drug -related rash 
g.Only if total bilirubin is elevated.
h.Only if CK is elevated .
i.HIV testing per loc al regulations .
j.After randomization, the investigator and Pfizer study personnel directly involved in the conduct of the trial 
will be kept blinded of the results of this test.
k.Com plete at screening .
7.2.2. Physical Examination
Complete Phy sical Examination :
Comp lete phy sical examinations must be performed by  the investigator, sub -investigator or a 
qualified health professional per local guidelines and will be performed at the visits identified 
in Schedule of Activities .  Complete phy sical examinations consist of assessments of general 
appearance which includes but is not limited to:g eneral appearance, head, ey es, ears, nose 
and throat (HEENT), mouth, heart; lungs; breast (optional); abdomen; external genitalia 
(optional); extremities; neur ologic function, back, ly mph nodes and skin (including presence 
of rash) . In addition, a dermatological full body exam must be performed at the Screening 
Visit by  the investigator, sub- investigator or a qualified health professional per local 
guidelines.
Targeted Examination
At all other visits, as defined in the Schedule of Activities, a targeted physical examination 
will be perf ormed by  the investigator, sub -investigator or a qualified health professional per 
local guidelines and should include skin (including presence of rash) , lungs, heart, abdomen 
and ly mph nodes and examination of body  systems where there are s ymptom complaints by  
the subject .  An y clinically significant changes from the baseline examination should be 
recorded as AEs.  
Additional phy sical examinations may  be performed at the investigator’s discretion.
7.2.3. Medical History , Height and Weight
Medical history  in addition to RA history  including history  of drug, alcohol, tobacco use , 
skin rash, skin infection, and an y dermal abnormalities that may  predispose to infection will 
be collected at Screening.  
Complete RA disease history includes RA diagnosis and collection of details of RA at 
Screening. This includes but is not limited to background, RA history  including dise ase 
durati on and extent of disease. 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 54Height and weight will be measured without the subject wearing shoes.  Height (inches or 
centimeters) and weight (lbs or kg) will be measured and recorded in the source document as 
indicated in the Schedule of Activities.
7.2.4. Pregnancy Testing
Pregnancy  tests are required to be done (if applicable) as specified in the Schedule of 
Activities. 
All pregnancy  tests used in this study , either urine or serum, must have a sensitiv ity of at 
least 25 mIU/mL  and must be performed by  a certified laboratory .  For female subjects of 
childbearing potential, 2negative pregnancy  tests are required before receiving 
investigational product (
1negative pregnancy  test at screening and 1at the baseline visit 
immediately  before investigational product administration).  Following a negative pregnancy  
test result at screening, appropriate contraception must be commenced and the second 
negative pregnancy  test result will then be required at the bas eline visit and within 5 days 
after the first day  of the menstrual period (counting the first day  of the menstrual period as 
Day 1) before the subject may  receive the investigational product.  In the absence of regular 
menstrual bleeding, the study  candida te should have used 2 forms of contraception for at 
least 1 month before the second pregnancy  test.  Pregnancy  tests will also be repeated at 
every  visit and at the end of the study to confirm that the subject has not become pregnant 
during the study .  Pre gnancy  tests will also be done whenever 1 menstrual cy cle is missed 
during the active treatment period and when potential pregnancy
 is otherwise suspected, and 
may be repeated if requested by  institutional review boards (IRBs)/ethics committees (ECs)
or if required b y local regulations.  In the case of a positive confirmed pregnancy , the subject 
will be withdrawn from administration of investigational product but will remain in the study  
for further follow -up..
7.2.5. Vital Signs 
(Blood Pressure , Pulse Rate and Te mperature)
Sitting BP, pulse rate, and temperature will be measured after approximately  5 minutes of 
rest at times specified in the Schedule of Activities.  It is preferred that the same 
measurement method be used consistently  throughout the study .  Additional collection times 
or changes to collection times will be permitted, as necessary  to ensure appropriate collection 
of safet y data.  When the timing of these measurements coincides with a blood collection, it 
is preferred that vi tal signs be obtained prior to the nominal time of blood collection. 
Sitting blood pressure will be measured with the subject’s arm supported at the level of the 
heart, and recorded to the nearest mmHg.  It is preferred that the same arm (preferabl y the 
dominant arm) be used throughout the study . 
A properl y sized and calibrated Blood Pressure (BP) cuff, will be used to measure BP each 
time.  The use of automated devices for measuring BP and pulse rate is acceptable, although, 
when done manually , pulse rat
e will be measured in the brachial/radial artery  for at least 
30seconds. 
It is preferred that bod y temperature be collected (either oral or tympanic ) and that the same 
method be used consistently  throughout the study.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 557.2.6. Electrocardiogram
Single t welve (12) lead ECGs will be obtained on all subjects.  All scheduled ECGs should 
be performed after the subject has rested quietly  for at least 10 minutes. 
When the timing of these measurements coincides with a blood collection, the ECG should 
be obtained prior to the nominal time of the blood collection, BP, and pulse rate. 
If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more 
times and the average of the three QTc or QRS values should be used to determine the 
subject’s eligibility .
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality.  It is important that leads are placed in the 
same positions each time in order to achieve precise ECG recordings.  I f a machine- read QTc 
value is prolonged, repeat measurements may  not be necessary  if a qualified phy sician’s 
interpretation determines that the QTc values are in the acceptable range.
An ECG may  also be performed at other times, at the discretion of the investigator if there 
were findings during a previous examination or in the case of a new/open adverse event 
(AE) .
7.2.7. Interferon -Gamma Release Assay
IGRA will be tested during screening or within 12 weeks prior to screening.  The following 
are acceptable assay s: QuantiFERON-TB Gold test (QFT -G), QuantiFERON-TB Gold 
In-Tube test (QFT -GIT) and T -SPOTTB test.  Blood sampling may  include 3 mL up to 
10mL of blood.  Site personnel should follow the processing and anal yses steps based on the 
assay  chosen.  Ensure incubation steps are followed as appropriate.
A documented IGRA test performed within 12 weeks prior to screening is acceptable.  IGRA 
product used, official reading and method, or test as per country  specific guidelines, must be 
located in the subjects source documentation. 
7.2.8. Chest X -Ray
Chest radiograph (posterior -anterior and lateral views are recommended, however local 
guidelines should be followed) or other appropriate diagnostic image (ie, Computerised 
Tomograph y (CT) or Magnetic Resonance Imaging (MRI) ) with no evidence of current, 
active TB or previous inactive TB, general infections, heart failure or malignancy  taken at 
Screening or within 12 weeks prior to Screening and read b y a qualified radiologist.  
Documentation of the official reading must be located and available in the source 
documentation.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 567.2.9. Infection Monitoring
Subjects will be monitored for development of any  infection (viral, bacterial, and fungal).  
Infections will be classified as either treated or non -treated infections.  All treated inf ections 
occurring during the study should be cultured if feasible and the results (eg, any  identified 
organisms or absence of growth) recorded in the CRF.
Treated infections are infections that:
Require antimicrobial therap y by any route of administration or; 
Require an y surgical intervention (eg, incision and drainage).
Treated infections will be further classified as serious or non- serious.  Serious infections are 
treated infections that:
Require parenteral antimicrobial therap y or; 
Required hospitaliza tion for treatment or; 
Meet other criteria that require the infection to be classified as a SAE.
A subject who experiences a serious infection should be discontinued from the study.  A 
serious infection should be reported as a SAE and should be listed as the reason for 
discontinuation in the CRF.  All serious infections occurring during the study  should undergo 
appropriate laboratory investigations, including culture, and the results (eg, any  identified 
organisms or absence of growth) be recorded in the CRF.
Subjects who experience non- serious infections that require treatment may  have their study  
drug temporaril y discontinued during treatment at the investigator’s discretion.  Consultation 
with the Pfizer medical monitor is available.  Temporary  discontinu ation of study  drug 
should be recorded in the CRF. 
7.2.10. Viral Surveillance
Blood samples will be collected according to the times outlined in the Schedule of Activities 
and may  be used to test viral load that may  include Cytomegalovirus (CMV ), Epstein- Barr 
Vir
us (EBV ), Varicella Zoster Virus ( VZV )and Herpes Simplex Virus Type 1 (HSV 1)and 
Herpes Simplex Virus Type 2 (HSV 2).
Due to delay ed reporting times for these assay s, the results might not be available along with 
the other study  tests . 
In addition to tim e points specified, a plasma sample for viral surveillance sample may also 
be taken at the time of an adverse event. 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 577.2.11. Dermatological Assessments
All subjects will have a dermatological full bod y exam at Screening Visit. Skin lesions will 
be evaluated as de fined in the National Cancer Institute Common Toxicity  Criteria for 
Adverse Events v4 .03(See Appendix 12, for Dermatology/Skin Category ) and managed as 
shown below. 
Table 7. Management of Dermatologica l Events
Derm atologic Event (CTCAE v 4.0 3)* Course of Managem ent
Acne/Acneiform Rash/Maculopapular Rash
Grade 1/2 1. Investigator’s discretion for w ithdrawing 
investigational product .
2. Execute reasonable monitoring .
3. Consider treatment with topical a gents such as 
clindamycin or corticosteroids .
Grade 3 1. Discontinue investigational product .
2. Monitor to resolution (defined as a Return to Baseline 
status) .
3. Consider treatment with topical agents such as 
clindamycin or corticosteroids .
Pruritus
Grade 1 Mild or localized 1. Investigator’s discretion for w ithdrawing 
investigational product .
2. Execute reasonable monitoring .
3. Consider treatment with topical agents such as 
clindamycin or corticosteroids .
Grade 2 Intense or w idespread 1. Discontinua tion of the investigational product may 
not be required unless condition is sustained >4 days 
or at the investigator’s discretion .
2. Execute reasonable monitoring .
3. Consider treatment with topical agents such as 
clindamycin or corticosteroids .
Grade 3 Intense or w idespread and interfering 
with activities of daily living1. Permanently discontinue investigational product .
2. Monitor to resolution (Return to Baseline) .
3. Consider treatment with topical agents such as 
clindamycin or corticosteroids .
* Refer to Appendix 12for clarification.
Herpetiform Rash 
For any  occurrence of a suspected herpetiform rash (e g, herpes zoster and herpes simplex), 
specimens for viral DNA anal ysis will be obtained: A swab of the affected area will be 
collected for confirmation; a blood sample for viral surveillance will be collected for the 
analysis of viral load. Details for these collections will be provided in the laboratory  manual.
Drug -Related Rash
All potential drug related reports of ra sh will be followed up until resolution or clinically  
stable or in agreement with Pfizer.   

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 58All events of rash should be treated according to i nternational and local guidelines for the 
treatment of rash, eg, where appropriate, topical corticosteroids and/ or agents such as 
antibiotics or antivirals could be prescribed. 
All subjects reporting an unexplained skin rash should be referred to a local dermatologist or 
appropriatel y qualified phy sician according to local guidelines for formal comprehensive 
dermat ologic evaluation.   A 4 mmpunch biopsy  will be taken unless there is a clear, 
non-drug related etiology (eg, infection, pre -existing condition) or other clinical rationale 
(eg,if the rash is present on the face it may  not be appropriate to take a biopsy )or if a
subject 
refuse sto have biops y performed .  The biopsy  will be sent to the local laboratory  for 
histological investigation of the rash in order to gain insight into potential etiology  of the 
rash. Note: For herpetiform rash, no biopsy  is required.
In addition to a biopsy  of suspected drug -related rash, a swab (for microbiological 
assessment) of the affected area will also be taken for culture and sensitivity  to assess for any  
bacterial , viral or fungal pathogens, if applicable .  Ablood sample for v iral surveillance will 
be collected for the anal ysis of viral load, if applicable. 
Subjects reporting rash should assess itch on a 10 -point numeric rating scale (NRS) provided 
by Pfizer (Appendix 14). Theinvestigator (and/o r designee) will enter this assessment into 
the data collection tool. 
Investigators (and /or designee) will complete required documentation and take appropriate 
photographs of the rash.
All de -identified biopsy  results , culture results, photographs, and a ny additional relevant test 
results will be forwarded to Pfizer (and/or designee) for review within 30 day s of receipt by  
the investigator.
An independent dermatologist contracted b y Pfizer will review all relevant data and 
summarize the data at the end of the study
7.2.12. Audiogram
All subjects will have an audiogram at times specified in the Schedule of Activities .
Audiogram testing at screening must be completed and results available b y the baseline visit 
(Visit 2) and audiogram testin g at Week 8 (Visit 7) must be completed and results available 
by the Week 12 visit (Visit 9). For subjects that terminate earl y from the study, if possible, 
efforts must be made to complete the audiology  testing and obtain the results.
When possible the s ubject should have the audiogram performed at the same evaluation 
center during the study . 
If there is a clinicall y meaningful , treatment related decline in hearing from baseline, the 
subject will be followed off treatment with appropriate testing at regu lar intervals, until 
hearing returns to baseline or is determined to be clinically  stable .

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 59The information from the audiogram will be entered into the data collection tool.  
Any de-identified audiogram results/reports and any  additional relevant test resu lts(if 
applicable) may  be requested to be forwarded to Pfizer (and/or designee) at any  time during 
the study . 
7.3.Pharmacokinetics
During all study  periods, blood samples to provide plasma for pharmacokinetic anal ysis of
PF-06651600 and for potential explora tory anal ysis of its metabolite(s) will be collected into 
appropriatel y labeled tubes containing K 2EDTA at times specified in the Schedule of 
Activities
.  The date and time of last dose and date and time of sample collection should be 
recorded in the source documents and data collection tool (e g,CRF/DCT).
7.3.1. Shipment of Pharmacokinetic Samples
The shipment address and contact information will be provided to the investigator site prior 
to the initiation of the study .
7.4.Exploratory Biomar kers
All blood, serum, plasma and urine samples for assessment of biomarkers must be collected 
prior to investigational product administration.  Any or all samples may  not be anal yzed, and 
data may  or may  not be included in the clinical study  report.  An y exploratory  biomarkers 
assessed would be to further understand RA or the effects PF- 06651600 only .
Analy sis of exploratory  endpoints may  be further detailed in the statistical anal ysis plan 
(SAP) or exploratory  analy sis plan (EAP).  Pooled or exploratory  analyses, if conducted, 
utilizing the retained exploratory  genomic and biomarker samples across PF -
06651600 
studies or across multiple programs will be documented in a separate anal ysis plan.
7.4.1. IFN- gamma -inducible protein 10 (IP-10)
Samples for anal ysis of IP -10 will be collected at the visits specified in the Schedule of 
Activities
.  The samples will be shipped to and analy zed by  a contract lab .  After
randomization, the investigator and Pfizer study  personnel directly  involved in the conduct of 
the trial will be kept blinded of the results of this test.
7.4.2. Anti -CCP and Rheumatoid Factor
A blood sample for assaying Anti -CCP and Rheumatoid Factor will be collected according to 
the Schedule of Activities.  After randomization, the investigator and Pfizer study  personnel 
directly  involved in the conduct of the trial will be kept blinded of the results of this test.
7.4.3. Samples for Exploratory Fluorescence Activated Cell Sorting ( FACS )analysis 
Whole blood samples will be collected according to the times specified in the Schedule of 
Activities
.  This blood sample will be used to run a standard Tcell, B cell and NK cell
subsets ( TBNK) panel, and may  be used to anal yze additional FACS analyses.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 607.5.Bank ed Biospecimens
Banked biospecimens will be collected from subjects for exploratory  research relating to the 
drug response in diseases of inflammation .  These collections are not typically associated 
with a planned assessment described in the protocol.   They will be handled in a manner that 
protects each subject’s privacy  and confidentiality .  Banked biospecimens will be assigned 
the subject’s study  identification code (ID) at the site.  The data generated from these banked 
biospecimens will also be indexed by this ID.  Biospecimens will be kept until destruction in 
facilities with access limited to authorized personnel, and biospecimen -derived data will be 
stored on password
-protected computer s ystems.  The key  between the subject’s ID and the 
subject’s dir ect personally  identify ing information (eg, name, address) will be held at the 
study  site.  Biospecimens will be used only  for the purposes described in the protocol and 
informed consent document; any  other uses require additional ethical approval.  Unless a 
time limitation is required by  local regulations or ethical requirements, biospecimens will be 
stored for man y years (no time limit) to allow for research in the future, including research 
conducted during the lengthy  drug -development process and also postmarketing research.  
Subjects may withdraw thei r consent for the use of their banked b iospecimens at any  time by  
making a request to the investigator; in this case, any remaining biospecimens will be 
destroyed, but data already  generated from the biospe cimens will continue to be available to 
protect the integrit y of existing analyses. 
Unless prohibited by  local regulations or ethics committee decision, a 4-mL blood genomic 
banked biospecimen Prep D1 (dipotassium edetic acid [ethylenediaminetetraacetic a cid] 
[K2EDTA] whole -blood collection optimized for DNA analysis) will be collected at the 
time specified in the Schedule of Activities section of the protocol to be retained for potential 
pharmacogenomic/genomic/biomarker analy ses related to drug response in diseases of 
inflammation .  For example, putative safety biomarkers, drug- metabolizing enzy me genes, 
drug-
transport protein genes, or genes thought to be related to the mechanism of drug action 
may be examined.  The primary  purpose is to examine DNA; however, the biospecimen may  
also be used to study  other molecules (eg, RNA, proteins, and metabolites).
If not collected on the designated collection day , collect at the next available time point when 
biospecimens are being collected in conjunction with a subject visit.  These samples must be 
collected before administration of the investigational product.
Additional banked b iospecimens to be retained for such exploratory  anal yses in this study  
include the following: 
Prep B1 (K2EDTA p lasma collection optimized for biomarker/proteomic/
metabonomic analysis): A 10 -mL blood biospecimen will be collected at times 
specified in the Schedule of Activities section of the protocol. 
Prep B2 (serum collection optimized f or biomarker/proteomic/metabonomic 
analysis) :a 10-mL blood biospecimen will be collected at times specified in the 
Schedule of Activities section of the protocol. 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 61Prep R1 (PAXGene whole -blood collection optimized for RNA analysis ):A 
2.5-mL blood biospecimen will be collected at times specified in the Schedule of 
Activities section of the protocol.
The banked biospecimens will be collected from all subjects unless prohibited by  local 
regulations or IRB/EC.
It is possible that the use of these biospecimens may result in commercially viable products.  
Subjects will be advised in the informed consent document that they  will not be compensated 
in this event.
7.5.1. Shipment of Biomarkers Samples
The shipment address and contact information for the lab will be provided to the investigator 
site. 
7.5.2. Additional Research
Unless prohibited by  local regulations or IRB/EC decision, subjects will be asked to indicate 
on the consent form whether they will allow banked biospecimen s to also be used to design 
and conduct research in order to gain a further understanding of other diseases and to 
advance science, including development of other medicines for patients
.
Subjects need not provide additional biospecimens for the uses descri bed in this section; the 
biospecimens specified in the Banked Biospecimens section will be used.  Subjects may  still 
participate in the stud y ifthey elect not to allow their banked b iospecimens to be used for the 
additional purposes described in this sect ion.
7.6.Rater Qualifications 
Tender and swollen joint counts will be evaluated by  adesignated study  staff member at the 
clinic. 
For consistency , the 
same assessor should perform all joint-count evaluations across the 
study  for an individual subject when po ssible.  It is especiall y important that the same 
assessor evaluate the subject at Screening, B aseline, and Week 8 to ensure integrity  of the 
eligibility  criteria and the clinical response up to the Week 8 primary  endpoint.  Only  if the 
assigned joint coun tassessor cannot be present, the joint counts should be performed b y a 
different study  staff member . 
The joint count assessor must have a background in performing RA or other clinical trials 
involving swollen and tender joint assessment and to have perso nal prior experience 
performing joint assessments. 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 628.ADVERSE EVENT REPORT ING
8.1.Requirements
The table below summarizes the requirements for recording safet y events on the CRF and for 
reporting safety events on the Clinical Trial (CT) Serious Adverse Event (SA E) Report Form 
to Pfizer Safety .  These requirements are delineated for 3 types of events: (1) SAEs; 
(2)non-serious adverse events (AEs); and (3) exposure to the investigational product under 
study  during pregnancy  or breastfeeding, and occupational expos
ure. 
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours of 
Awareness
SAE All All
Non-serious AE All None
Exposure to the 
investigational product 
under study  during 
pregnancy  or 
breastfeeding, and 
occupa tional exposureAll (regardless of whether 
associated with an AE), 
except occupational 
exposureExposure during pregnancy , 
exposure via breastfeeding, 
occupational exposure 
(regardless of whether 
associated with an AE)
All observed or volunteered events r egardless of treatment group or suspected causal 
relationship to the investigational product(s) will be reported as described in the following 
paragraphs.
Events listed in the table above that require reporting to Pfizer Safety  on the CT SAE Report 
Form wi thin 24 hours of awareness of the event by the investigator are to be reported 
regardless of whether the event is determined by the investigator to be related to an 
investigational product under study .  In particular, if the SAE is fatal or life -threatenin g, 
notification to Pfizer Safety  must be made immediately , irrespective of the extent of available 
event information.  This time frame also applies to additional new (follow -up) information on 
previously  forwarded reports.  I n the rare situation that the i nvestigator does not become 
immediately  aware of the occurrence of an event, the investigator must report the event 
within 24 hours after learning of it and document the time of his/her first awareness of the 
event.
For each event, the investigator must pu rsue and obtain adequate information both to 
determine the outcome and to assess whether it meets the criteria for classification as an SAE 
(see the Serious Adverse Events section below).  In addition, the investigator may  be 
requested b y Pfizer Safety to obtain specific follow -up information in an expedited fashion.  
This information is more detailed than that recorded on the CRF.  In general, this will include 
a description of the event in sufficient detail to allow for a complet e medical assessment of 
the case and independent determination of possible causalit y.  An y information relevant to 
the event, such as concomitant medications and illnesses, must be provided.  I n the case of a 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 63subject death, a summary of available autopsy  findings must be submitted as soon as possible 
to Pfizer Safety .  An y pertinent additional information must be reported on the CT SAE 
Report Form; additional source documents (eg, medical records, CRF, laboratory  data) are to 
be sent to Pfizer Safet y ONLY upon request.
As part of ongoing safet y reviews conducted b y the sponsor, an y non -serious AE that is 
determined b y the sponsor to be serious will be reported by the sponsor as an SAE.  To assist 
in the determination of case seriousness, further information may be requested from the 
investigator to provide clarity  and understanding of the event in the context of the clinical 
study .
8.1.1. Additional Details on Recording Adverse Events on the CRF
All events detailed in the table above will be recorded on the AE page( s) of the CRF.  I t 
should be noted that the CT SAE Report Form for reporting of SAE information is not the 
same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE Report 
Form for reporting of SAE information.
8.1.2. Eliciting Adverse Event Information
The investigator is to record on the CRF all directly  observed AEs and all AEs 
spontaneously  
reported b y the stud y subject/ legally  acceptable representative .  In addition, each study  
subject /legally  acceptable representative will be questioned about the occurrence of AEs in a 
non-leading manner.
8.1.3. Withdrawal From the Study Due to Adver se Events (see also the 
Subject 
Withdrawal/Early Withdrawal section)
Withdrawal due to AEs should be distinguished from withdrawal due to other causes, 
according to the definition of AE noted below, and recorded on the CRF. 
When a subject withdraws from the study  because of an SAE, the SAE must be recorded on 
the CRF and reported, as appropriate, on the CT SAE Report Form, in accordance with the 
Requirements section above.
8.1.4. Time Period for Collecting AE/SAE Information
The time per iod for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each subject begins from the time the subject provides informed consent, which 
is obtained before the subject’s participation in the study  (ie, before undergoing any  
study-related procedure and/or receiving investigational product), through and including a 
minimum of 28 calenda r day safter the last administration of the investigational product.
For subjects who are screen failures, the active collection period ends when screen failure 
status is determined.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 648.1.4.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a subject during the active collection period are reported to Pfizer 
Safety  on the CT SAE Report Form.
SAEs occurring in a subject after the active collection period has ended are reported to Pfizer 
Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility  of being related to investigational 
product must be reported to Pfizer Safety .
Follow up by  the investigator continues throughout and after the active collection period and 
until the event or its sequelae resolve or stabilize at a level acceptable to the investigator, and 
Pfizer concurs with that assessment.
8.1.4.2. Recording Non -serious AEs and SAEs on the CRF
During the active collection period, both non-serious AEs and SAEs are recorded on the 
CRF.
Follow -up by  the investigator may  be required until the event or its sequelae resolve or 
stabilize at a level acceptable to the investigator, a
nd Pfizer concurs with that assessment.
8.1.5. Causality Assessment
The investigator’s assessment of causalit y must be provided for all AEs (serious and 
non-serious); the investigator must record the causal relationship on the CRF, and report such 
an assessment i n accordance with the SAE reporting requirements, if applicable.  An 
investigator’s causalit y assessment is the determination of whether there exists a reasonable 
possibility  that the investigational product caused or contributed to an AE; generall y the fa cts 
(evidence) or arguments to suggest a causal relationship should be provided.  If the 
investigator does not know whether or not the investigational product caused the event, then 
the event will be handled as “related to investigational product” for repo rting purposes, as 
defined b y the sponsor.  If the investigator's causality
 assessment is “unknown but not 
related” to investigational product, this should be clearl y documented on study  records. 
In addition, if the investigator determines that an SAE is associated with study procedures, 
the investigator must record this causal relationship in the source documents and CRF, and 
report such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
8.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities
AE reporting, including suspected unexpected serious adverse reactions, will be carried out 
in accordance with applicable local regulations.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 658.2.Definitions
8.2.1. Adverse Events
An AE is an y untoward medica l occurrence in a study  subject administered a product or 
medical device; the event need not necessaril y have a causal relationship with the treatment 
or usage.  Examples of AEs include, but are not limited to: 
Abnormal test findings;
Clinically  significa nt signs and sy mptoms;
Changes in physical examination findings;
Hypersensitivity ;
Progression/worsening of underl ying disease ;
Drug abuse;
Drug dependency .
Additionally , AEs may  include signs and s ymptoms resulting from:
Drug overdose;
Drug withdrawal;
Drug misuse; 
Drug interactions;
Extravasation;
Exposure during pregnancy  (EDP);
Exposure via breastfeeding;
Medication error;
Occupational exposure.
8.2.2. Abnormal Test Findings
Abnormal objective test findings should be recorded as AEs when an y of the following 
conditions are met: 
Test result is associated with accompan ying symptoms; and/or

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 66Test result requires additional diagnostic testing or medical/surgical intervention; 
and/or
Test result leads to a change in study  dosing (outside of any  protocol -specified d ose 
adjustments) or discontinuation from the study , significant additional concomitant 
drug treatment, or other therap y; and/or
Test result is considered to be an AE b y the investigator or sponsor.
Merel y repeating an abnormal test, in the absence of an y of the above conditions, does not 
constitute an AE.  An y abnormal test result that is determined to be an error does not require 
recording as an AE.
8.2.3. Serious Adverse Events
A serious adverse event is any  untoward medical occurrence at any  dose that:
Results in death;
Is life -threatening (immediate risk of death);
Requires inpatient hospitalization or prolongation of existing hospitalization;
Results in persistent or significant disability /incapacity  (substantial disruption of the 
ability  to conduct normal lif e functions);
Results in congenital anomaly /birth defect.
Or that is considered to be:
An important medical event.
Medical and scientific judgment is exercised in determining whether an event is an important 
medical event.  An important medical event may  not be immediately  life-threatening and/or 
result in death or hospitalization.  However, if it is determined that the event may  jeopardize 
the subject or may  require intervention to prevent one of the other AE outcomes, the 
important medical event should be reported as serious.
Examples of such events are intensive treatment in an emergency  room or at home for 
allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; 
or development of drug dependency  or drug abuse.
8.2.4. Hospitalization
Hospitalization is defined as an y initial admission (even less than 24 hours) in a hospital or 
equivalent healthcare facility , or any  prolongation of an existing admission.  Admission also 
includes transfer within the hospital to an acute/intensiv e care unit (eg, from the psy chiatric 
wing to a medical floor, medical floor to a coronary  care unit, or neurological floor to a 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 67tuberculosis unit).  An emergency  room visit does not necessarily constitute a hospitalization; 
however, the event leading to t he emergency  room visit is assessed for medical importance.
Hospitalization does not include the following:
Rehabilitation facilities;
Hospice facilities;
Respite care (eg, caregiver relief);
Skilled nursing facilities;
Nursing homes;
Same -day surgeries (a s outpatient/same -day/ambulatory  procedures).
Hospitalization or prolongation of hospitalization in the absence of a precipitating clinical 
AE is not in itself an SAE.  Examples include:
Admission for treatment of a preexisting condition not associated wit h the 
development of a new AE or with a worsening of the preexisting condition (eg, for 
workup of a persistent pretreatment laboratory  abnormality );
Social admission (eg, subject has no place to sleep);
Administrative admission (eg, for yearly physical exa mination);
Protocol -specified admission during a study  (eg, for a procedure required by  the study  
protocol);
Optional admission not associated with a precipitating clinical AE (eg, for elective 
cosmetic surgery );
Hospitalization for observation without a m edical AE;
Preplanned treatments or surgical procedures.  These should be noted in the baseline 
documentation for the entire protocol and/or for the individual subject .
Diagnostic and therapeutic noninvasive and invasive procedures, such as surgery , should not 
be reported as SAEs.  However, the medical condition for which the procedure was 
performed should be reported if it meets the definition of an SAE.  For example, an acute 
appendicitis that begins during the reporting period should be reported if the S AE 
requirements are met, and the resulting appendectomy  should be recorded as treatment of the 
AE.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 688.3.Severity Assessment
If required on the AE page of the CRF, the investigator will use the adjectives MILD, 
MODERATE, or SEVERE to describe the maximum intensi ty of the AE.  For purposes of 
consistency , these intensity  grades are defined as follows:
MILD Does not interfere with subject's usual function.
MODERATE Interferes to some extent with subject's usual function.
SEVERE Interferes significantl y with subj ect's usual function.
Note the distinction between the severit y and the seriousness of an AE.  A severe event is not 
necessarily  an SAE.  For example, a headache may  be severe (interferes significantly  with 
the subject's usual function) but would not be classified as serious unless it met one of the 
criteria for SAEs, listed above.
8.4.Special Situations
8.4.1. Protocol -Specified Serious Adverse Events
There are no protocol -specified SAEs in this study.  All SAEs will be reported to Pfizer 
Safety  by the investigator as described in previous sections, and will be handled as SAEs in 
the safet y database. 
8.4.2. Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolera tors,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some subjects, transaminase elevations are a harbinger of a more 
serious potential outcome.  These subjects fail to adapt and therefore are "susceptible" to 
progressiv e and serious liver injury , commonly  referred to as drug- induced liver injury  
(DILI).  Subjects who experience a transaminase elevation above 3 times the upper limit of 
normal ( ×ULN) should be monitored more frequently  to determine if they are an “adaptor ” 
or are “susceptible.”
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (TBili) elevations (>2 ×ULN) by  several 
days or weeks.  The increase in TBili ty picall y occ urs while AST/ALT is/are still elevated 
above 3 ×ULN (ie, AST/AL T and TBili values will be elevated within the same lab sample).  
In rare instances, b y the time TBili elevations are detected, AST/ALT values might have 
decreased.  This occurrence is still regarded as a potential DILI.  Therefore, abnormal 
elevations in either AST OR AL T in addition to TBili that meet the criteria outlined below 
are considered potential DILI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medical events, even before all other possible causes of liver injury 
have been excluded.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 69The threshold of laboratory  abnormalities for a potential DILI case depends on the subject’s 
individual baseline values and underl ying conditions.  Subjects who present with the 
following laboratory  abnormalities should be evaluated further as potential DILI (Hy ’s law) 
cases to definitivel y determine the etiology of the abnormal laboratory  values:
Subjects with AST/AL T and TBili baseline values within the normal range who
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available;
For subjects with baseline AST OR ALT ORTBili values above the ULN, the 
following t hreshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or > 8×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 
The subject should return to the investigator s
ite and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results.  This evaluation should 
include laboratory  tests, detailed history , and physical assessment. 
In addition to repeating measurements of AST and AL T and TBili, laboratory  tests should 
include albumin, creatine kinase (CK), direct and indirect bilirubin, gamma -glutamyl 
transferase (GGT), prothrombin time (PT)/international normalized ratio (INR), total bile 
acids, alkaline phosphatase and acetaminophen drug and/or protein adduct levels.  
Consideration should also be given to drawing a separate tube of clotted blood and an 
anticoagulated tube of blood for further testing, as needed, for further contemporaneous 
analyses at the time of the recognized initia l abnormalities to determine etiology .  A detailed 
history , including relevant information, such as review of ethanol, acetaminophen (either b y 
itself or as a coformulated product in prescription or over -the-counter medications) , 
recreational drug, supplement (herbal) use and consumption, family  history , sexual history , 
travel history , history  of contact with a jaundiced person, surgery , blood transfusion, history  
of liver or allergic disease, and potential occupational exposure to chemicals, should be 
collected.  Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging 
(eg, biliary  tract) may  be warranted. 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 70All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the Liver Function Test (LFT)abnormalities has y et been found.  Such 
potential DILI (Hy’s law) cases are to be reported as SAEs, irrespective of availability 
of all the results of the i nvestigations performed to determine etiology of the LFT 
abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
8.4.3. Exposure to the Investigational Product During Pregnancy or Breastfeeding, and 
Occupational Exposure
Exposure to the investigational product under study  during pregnancy  or breastfeeding and 
occupational exposure are reportable to Pfizer Safety  within 24 hours of investigator 
awareness.
8.4.3.1. Exposure During Pregnancy
For both unapproved/unlicensed products and for marketed products, an exposure during 
pregnancy  (EDP) occurs if:
A female becomes, or is found to be, pregnant either while receiving or having been 
exposed (eg, because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pregnant after discontinuing and/or 
being exposed to the investigational product;
An example of environmental exposure would be a case involving direct contact with 
a Pfizer product in a pregnant woman (eg, a nurse reports that she is pregnant and has 
been exposed to chemotherapeutic products).
A male has been exposed (eg, because of treatment or environmental exposure) to the 
investigati onal product prior to or around the time of conception and/or is exposed 
during his partner’s pregnancy .
If a subject or subject’s partner becomes or is found to be pregnant during the subject’s 
treatment with the investigational product, the investigator must report this information to 
Pfizer Safety  on the CT SAE Report Form and an EDP supplemental form, regardless of 
whether an SAE has occurred.  In addition, the investigator must submit information 
regarding environmental exposure to a Pfizer product in a pregnant woman (eg, a subject 
reports that she is pregnant and has been exposed to a cy totoxic product by inhalation or 
spillage) to Pfizer Safety  using the EDP supplemental form.  This must be done irrespective 
of whether an AE has occurred and within 24 hours of awareness of the exposure.  The 
information submitted should include the anticipated date of delivery  (see below for 
information related to termination of pregnancy ).

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 71Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP supplemental form.  In the case of a live birth, the structural 
integrity  of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrity  of the terminated fetus should be assessed by  gross visual inspection (unless 
pre-procedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortio n, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.
Additional information abou t pregnancy  outcomes that are reported to Pfizer Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed abortion;
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs.  In additi on, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the investigational product.
Additional information regarding the EDP may  be requested by  the sponsor. Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).  In the case of paternal exposure, the 
investigator will provide the subject with the Pregnant Partner Release of Information Form 
to deliver to his partner.  The investigator must document in the source documents that the 
subject was given the Pregnant Partner Release of Information Form to provide to his 
partner.
8.4.3.2. Exposure During Breastfeeding
Scenarios of exposu re during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to Pfizer Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding report is not created when a Pfiz er 
drug specifically  approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the exposu re during breastfeeding.
8.4.3.3. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact with the 
product, which may  or may  not lea d to the occurrence of an AE.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 72An occupational exposure is reported to Pfizer Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pertain to a subject enrolled in the study , the 
information is not recorded on a CRF; however, a copy  of the completed CT SAE Report 
Form is maintained in the investigator site file.
8.4.4. Medication Errors 
Other exposures to the investigational product under study  may  occur in clinical trial settings, 
such as medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to Pfizer Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if assoc iated with an SAE
8.4.4.1. Medication Errors
Medication errors may  result from the administration or consumption of the investigational 
product b y the wrong subject, or at the wrong time, or at the wrong dosage strength .
Medication errors include :
Medication erro rs involving subject exposure to the investigational product;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the participating subject.
Such medication errors occurring to a stud y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately .
Whether or not the medication error is accompanied by  an AE, as determ ined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and non -serious, are recorded on an AE page of the 
CRF. 
Medication errors should be reported to Pfizer Saf ety within 24 hours on a CT SAE Report 
Form only when associated with an SAE .
9. DATA ANALYSIS/STATIS TICAL METHODS
Detailed methodolog y for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in a statistical anal ysis plan (SAP), which will be 
maintained by  the sponsor.  The SAP may  modify  what is outlined in the protocol where 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 73appropriate; however, any  major modifications of the primary  endpoint definitions or their 
analyses will also be reflected in a pr otocol amendment.
The information from the placebo arm will be combined with the historic database using 
Bayesian statistical methodology .  The historic study  data base will include the data obtained 
from Phase III tofacitinib trials available to the Spons or.  The integration details and 
historical data specifications will be detailed in SAP.
  The integration with historical data 
will involve application of statistical procedures attempting maximization of the 
commensurability  between the current trial and the subgroup of the historical data used for 
synthesizing the prior distribution. 
9.1.Sample Size Determination
The primary  endpoint of the study  will be the change from baseline in SDAI at 8 weeks.  The 
study  will enroll approximately  50completers allocated as follows: 
PF-06651600 (200 mg) (N) Placebo (N)
30 20
Assuming a 15% dropout rate*the study  will enroll approximately  60subjects .
The study  will have over 90% power to detect separation from placebo, assuming a 13 point 
difference in response betwee n the placebo and 200 mg arm (standard deviation is assumed 
to be 14 points for both arms*) and controlling Type -I error rate at 5% level.  More detailed 
sample size considerations will be discussed in the SAP.
*Based on information from Phase 3 tofacitin ib studies. 
9.2.Efficacy Analysis
9.2.1. Analysis of the Primary Endpoint 
Theprimary efficacy  analy sis will be conducted on SDAI  change from baseline at 8 weeks. 
Analy sis will include data on PF -06651600 and placebo arms. 
Analy sis details will be outlined in sta tistical analysis plan.   The anal ysis will include: 
ANCOVA models adjusting for SDAI baseline value; Bay esian anal ysis of posterior 
distributions of the SDAI scores and placebo adjusted change from baseline; Advanced data 
visualization techniques for stati stical result presentation. 
The primary  anal ysis will be conducted on intention -to-treat (ITT) population (randomized 
subjects with at least one post baseline value) .  Sensitivity  analy sis and handling of the 
missing values will be outlined in the SAP.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 749.2.2. Analysis of Secondary Endpoints
Analy ses of the secondary  endpoints will be outlined in the SAP.  Continuous and discrete 
modeling techniques will be applied whenever applicable.  The statistical summaries will be 
presented b y dose groups.  The correlations between the endpoints will be anal yzed. 
9.3.Analysis of Other Endpoints
Analy sis of other endpoints will be conducted as deemed appropriate.  Continuous and 
discrete modelling techniques will be applied whenever applicable.  Distribution summaries 
will be pre sented b y means of summary tables anddata visualization methods.
9.4.Randomization
The indicator of prior exposure and inadequate response to anti- TNFtreatment will be used 
as a stratification variable for randomization.
  Randomization will be stratified to achieve 
equal proportion of anti -TNFinade quate responders in all arms.
9.5.Safety Analysis
All clinical AEs, SAEs, TEAEs, withdrawal due to AEs, ECGs, vital signs and safet y 
laboratory  data will be reviewed and summarized on an ongoing basis during the stu dy to 
evaluate the safet y of subjects. 
The safet y analysis set will include all subjects who have received at least one dose of IP.  
Safety  data will be presented in tabular and/or graphical format and summarized 
descriptivel y, where appropriate.  All saf ety endpoints will be listed and summarized in 
accordance with Pfizer Standards.  Categorical outcomes (eg, AEs) will be summarized by  
subject counts and percentage.  Continuous outcome (eg, BP, pulse rate, etc) will be 
summarized using N, mean, median, st andard deviation, etc.  Change from baseline in 
laboratory  data, ECGs and vital signs will also be summarized.  Subject listings will be 
produced for these safet y endpoints accordingl y.
9.6.Data Monitoring Committee 
This study  will not use a data monitoring committee.
9.7.PK/PD Unblinding Plan
A PK/PD unblinding plan approved b y the clinical lead, clinical pharmacology  lead and 
statistical lead will be in place to describe the procedures to be employ ed in safeguarding the 
study  blind for members of this study  team.
  These procedures will be in accordance with 
applicable Pfizer SOPs for releasing randomization codes and breaking the study  blind. 
Under this plan a group of Statisticians, PK/PD data provider, PK/PD anal yst and PK/PD 
support would be unblinded in order to initiate the building of statistical models of the PK, 
dose/response as well as exposure/response analysis models and conduct associated 
simulations.   The aim of this work would be to facilitate a fuller interpretation of the study 
upon completion ( at appropriate interim milestone). 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 75This group will not serve on the study  team during the period of earl y unblinding.  The 
unblinding may  occur after the last subject has been randomized.  The details of the 
procedures will be described in the PK/PD Unbli
nding Plan for Modelling and Simulation for 
study  B7981006 which will be finalized prior to the start of the PK/PD unblinding. 
9.8.
Unblinding for Biomarkers
In order to expedite the analy ses of the biomarkers, an unblinded team may  review the 
biomarker data ( including exploratory  biomarkers) and exposure data on an ongoing basis.   
This group will minimally  be comprised of a bioanaly st and a statistician, but may  also 
include clinicians/precision medicine personnel, clinical pharmacologist and PK/PD 
analyst/sup port staff as appropriate.   This group will be unblinded when needed in order to 
conduct the analy ses of the biomarkers in accordance with a biomarker data anal ysis plan, 
and will be independent of the study  team.   This unblinding process will be in accord ance 
with Pfizer SOPs related to Releasing Randomization Codes and Breaking the Blind and will 
not have an y impact on the conduct of the stud y. 
The biomarker plan, approved by  the clinical lead, clinical pharmacology  lead and statistical 
lead, will be in place to describe the procedures to be employ ed in safeguarding the study  
blind for members of the study  team.
  The biomarker plan will outline the range of possible 
analyses and provide details of the decision- making process regarding unblinding.
10.QUALITY CONTROL AND QUALITY ASSURANCE
Pfizer or its agent will conduct periodic monitoring visits during study  conduct to ensure that 
the protocol and Good Clinical Practices ( GCPs) are being followed.  The monitors may  
review source documents to confirm that the data recorded on CRFs areaccurate.  The 
investigator and institution will allow Pfizer monitors/auditors or its agents and appropriate 
regulatory  authorities direct access to source documents to perform this verification.   This 
verification may  also occur after stud y completion.
During study  conduct and/or after study  completion, t
he investigator site may  be subject to 
review b y the IRB/EC , and/or to quality  assurance audits performed by  Pfizer, or companies 
working with or on behalf of Pfizer, and/or to i nspection by  appropriate regulatory  
authorities.
The investigator(s) will notify  Pfizer or its agents immediately  of any  regulatory  inspection 
notification in relation to the study .Furthermore, the investigator will cooperate with Pfizer 
or its agents to prepare the investigator site for the inspection and will allow Pfizer or its 
agent, whenever feasible, to be present during the inspection.
  The investigator site and 
investigator will promptly resolve an y discrepancies that are identified between the st udy 
data and the subject's medical records.  The investigator will promptly  provide copies of the 
inspection findings to Pfizer or its agent.  Before response submission to the regulatory 
authorities, the investigator will provide Pfizer or its agents with an opportunity  to review 
and comment on responses to any  such findings.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 76It is important that the investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the 
process.
11.DATA HANDLING AND RE CORD KEEPING
11.1. Case Report Forms/Electronic Data Record
As used in this protocol, the term CRF should be understood to refer to either a paper form or 
an electronic data record or both, depending on the data collection me thod used in this study .
A CRF is required and should be completed for each included subject.  The completed 
original CRFs are the sole propert y of Pfizer and should not be made available in any form to 
third parties, except for authorized representatives of Pfizer or appropriate regulatory  
authorities, without written permission from Pfizer.
The investigator has ultimate responsibility  for the collection and reporting of all clinical, 
safet y
,and laboratory  data entered on the CRFs and any  other data colle ction forms (source 
documents) and ensuring th at they  are accurate, authentic /original, attributable, complete, 
consistent, legible, timely  (contemporaneous), enduring , and available when required.  The 
CRFs must be signed by  the investigator or by  an auth orized staff member to attest that the 
data contained on the CRFs are true. Any correcti ons to entries made in the CRFs or source 
documents must be dated, initialed ,and explained (if necessary ) and should not obscure the 
original entry . 
In most cases, t he source documents are the hospital or the phy sician subject chart.  In these 
cases , data collected on the CRFs must match the data in those charts. 
In some cases, the CRF may  also serve as the source document.  In these cases, a document 
should be avail able at the investigator site and at Pfizer that clearl y identifies those data that 
will be recorded on the CRF, and for which the CRF will stand as the source document.
11.2. Record Retention
To enable evaluations and/or 
inspections/ audits from regulatory  authorities or Pfizer, the 
investigator agrees to keep records, including the identity  of all participating subjects 
(sufficient information to link records, eg,CRFs and hospital records), all original signed 
informed consent documents, copies of all CRFs, safety reporting forms, source documents, 
and detailed records of treatment disposition, and adequate documentation of relevant 
correspondence ( eg,letters, meeting minutes, and telephone call reports).  The records should 
be retained b y the investigator acco rding to the ICH guidelines, according to local 
regulations, or as specified in the clinical study agreement (CSA) , whichever is longer.
If the investigator becomes unable for an y reason to continue to retain study records for the 
required period ( eg, retirement, relocation), Pfizer should be prospectivel y notified.  The 
study  records must be transferred to a designee acceptable to Pfizer , such as another 
investigator, another institution, or an independent third party  arranged by  Pfizer. 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 77Investigator reco rds must be kept for a minimum of 15 years after completion or 
discontinuation of the study or for longer if required by applicable local regulations. 
The investigator must obtain Pfizer's written permission before disposing of an y records, 
even if retent ion requirements have been met.
12.ETHICS
12.1. Institutional Review Board/Ethics Committee
It is the responsibility  of the investigator to have prospective approval of the study  protocol, 
protocol amendments, informed consent documents, and other relevant document s, 
eg,recruitment advertisements, if applicable, from the I RB/EC.  All correspondence with the
IRB/EC should be retained in the investigator f ile.  Copies of IRB/EC approvals should be 
forwarded to Pfizer.
The only  circumstance in which an amendment may  be initiated prior to IRB/EC approval is 
where the change is necessary  to eliminate apparent immediate hazards to the subjects.  In 
that event, the investigator must notify  the IRB/EC and Pfizer in writing immediately  after 
the implementation.
12.2. Ethical Condu ct of the Study
The study  will be conducted in accordance with the protocol, legal and regulatory  
requirements, and the general principles set forth in the I nternational Ethical Guidelines for 
Biomedical Research Involving Human Subjects (Council for Inter national Organizations of 
Medical Sciences 2002), ICH Guideline for G ood Clinical Practice , and the Declaration of 
Helsinki .
12.3. Subject Information and Consent
All parties will ensure protection of subject personal data and will not include subject names 
or other identifiable data in any reports, publications, or other disclosures, except where
required b y law.
When study  data are compiled for transfer to Pfizer and other authorized parties, s ubject 
name s, address es, and other identifiable data will be replac ed by numerical code sbased on a 
numbering sy stem provided by  Pfizer in order to de -identify  study  subject s . The investigator
site will maintain a confidential list of subjects who participated in the study ,linking each 
subject’s numerical code to his or heractual identity .  In case of data transfer, Pfizer will 
maintain high standards of confidentialit y and protection of subjects’ personal data consistent 
with applicable privacy  laws .
The informed consent document sand an y subject recruitment materials must be in 
compliance with ICH GCP, local regulatory  requirements, and legal requirements, including 
applicable privacy  laws .

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 78The informed consent document s used during the informed consent process and an y subject 
recruitment materials must be reviewed andapproved by Pfizer , approved by  the IRB/EC
before use , and available for inspection. 
The investigator must ensure that each study  subject ,or his or her legall y acceptable 
representative is fully  informed about the nature and objectives of the study  and possible 
risks associated with participation. 
Whenever consent is obtained from a subject’s legally  acceptable representative, the 
subject’s assent (affirmative agreement) must subsequently
 be obtained when the subject has 
the capacity  to provide assent, as determined b y the IRB/EC.  If the investigator determines 
that a subject’s decisional capacit y is so limited he/she cannot reasonabl y be cons ulted, then, 
as permitted b y the IRB/EC and consistent with local regulatory  and legal requirements, the 
subject ’s assent may  be waived with source documentation of the reason assent was not 
obtained.  If the stud y subject does not provide hisor herown consent, the source documents
must record why the sub ject did not provide consent (eg
, minor, decisionally  impair ed adult), 
how the investigator determined that the person signing the consent was the subject’s legal ly 
acceptable representative, the consent signer’s relationship to the study  subject (eg, parent, 
spouse) ,and that the subject’s assent was obtained or w aived.  If assent is obtained verball y
,
it must be documented in the source documents.
The investigator, or a person designated b y the investigator, will obtain written informed 
consent from each subject or the subject's legall y acceptable representative ,before an y 
study -specific activity  is performe d.  The investigator will retain the original of each subject's 
signed consent document .
12.4. Reporting of Safety Issues and S erious B reaches of the Protocol or ICH GCP
In the event of any prohibition or restrictio n imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of any  new 
information that 
might influence the evaluation of the benefits and risks of the investigational 
product, Pfizer should be informed immediately . 
In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study subjects against an y immediate hazard, and of 
any serious breaches of this protocol or of I CH GCP that the investigator becomes aware of .
13.DEFINITION OF END OF TRIAL
13.1. End of Trial in a Member State 
End of trial in a Member State of the European Union is defined as the time at which it is 
deemed that a sufficient number of subjects have been recru ited and completed the study  as 
stated in the regulatory  application (i e,clinical trial application [CTA ]) and ethics application 
in the Member State.  Poor recruitment (recruiting less than the anticipated number in the 
CTA) by  a Member State is not a re ason for premature termination but is considered a 
normal conclusion to the study  in that Member State.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 7913.2. End of Trial in A llOther Participating Countries 
End of trial in all other participating countries is defined as l ast subject last visit (LSLV).
14.SPON SOR DISCONTINUATION CRITERIA
Premature termination of this study  may  occur because of a regulatory  authority  decision, 
change in opinion of the IRB/EC , orinvestigational product safety  problems, or at the 
discretion of Pfizer.  In addition, Pfizer retains the right to discontinue development of 
PF
-06651600 at any  time.If a study  is prematurel y terminated, Pfizer will promptly  notify  the 
investigator.  After notification, the investigator must contact all participating subjects and 
the hospital pharmacy  (ifapplicable) within 1month .  As directed b y Pfizer, all study 
materials must be collected and all CRFs completed to the greatest extent possible.
15.PUBLICATION OF STUDY RESULTS
15.1. Communication of Results by Pfizer
Pfizer fulfills its commitment to publicly  disclose clinical trial results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials 
Database (EudraCT), and/ or www.pfizer.com, and other public registries in accordance with 
applicable local law s/regulations. 
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial US Basic Results on www.clinicaltrials.gov for Pfizer- sponsored 
interventional studies ( conducted in subjects) that evaluate the safet y and/or efficacy of a 
Pfizer product , regardless of the geographical location in which the study  is conducted.  US 
Basic Results are submitted for posting within 1 year of the primary completion date (PCD) 
for studies in adult populations or within 6 months of the PCD for studies in pediatric 
populations.
PCD is defined as the date that the final subj
ect was examined or received an intervention for 
the purposes of final collection of data for the primary  outcome, whether the clinical study  
concluded according to the pre specified protocol or was terminated.
EudraCT
Pfizer posts European Union ( EU)Basic Results on EudraCT for all Pfizer -sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 year of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in ped iatric populations.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 80www.pfizer.com
Pfizer posts Public Disclosure Sy nopses (clinical study  report sy nopses in which any  data 
that could be used to identify individual subjects has been removed) on www.pfizer.com for 
Pfizer -sponsored interventional studies at the same time the US Basic Results document is 
posted to www.clinicaltrials.gov.
15.2. Publications by Investigators
Pfizer supports the exercise of academic freedom and has no objection to publication by  the 
principal investigator (PI) of the results of the study based on information collected or 
generated b y the 
PI, whether or not the results are favorable to the Pfizer product.  However, 
to ensure aga inst inadvertent disclosure of confidential i nformation or unprotected 
inventions, 
the investigator will pro vide Pfizer an opportunity  to review any  proposed 
publication or other t ype of disclosure of the results of the s tudy (collectively , “publication”) 
before it is submitted or otherwise disclosed.
The i nvestigator will provide any publication to Pfizer at le ast 30 days before 
it is submitted 
for publication or otherwise disclosed. If any patent action is required to protect intellectual 
propert y rights, the investigator agrees to delay  the disclosure for a period not to exceed an 
additional 60 days.
The i nvestigator will, on request, remove an y previously  undisclosed confidential 
information bef ore disclosure, except for any  study-or Pfizer product -related information 
necessary  to the appropriate scientific presen tation or understanding of the s tudy results.
If the study  is part of a multi centerstudy , the investigator agrees that the first publication is 
to be a joint publication covering all investigator sites, and that an y subsequent 
publications 
bythe PI will reference that primary  publication . However, if a joint manuscript has not 
been submitted for publication within 12 months of co
mpletion or termination of the s tudy at 
all participating sites, the investigator is free to publish separatel y, subject to the other 
requirements of this s ection.
For all publications relating to the s tudy, the i nstitution will comply  with recognized ethical 
standards concerning publications and authorship, including Section II -“Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requirements f or 
Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, 
established by  the International Committee of Medical Journal Editors.
Publication of study  results is also provided for in the CSA between Pfizer and the 
institut
ion.  I n this section entitled Publications by  investigator s, the defined terms shall have 
the meanings given to them in the CSA.
If there is an y conflict between the CSA and an y a
ttachments to it, the terms of the CSA 
control.  If there is an y conflict be tween this protocol and the CSA, this protocol will control 
as to any  issue regarding treatment of s tudy subjects, and the CSA will control as to all other 
issues.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 8116.REFERENCES
1. Anderson J et al., Rheumatoid Arthritis Disease Activity  Measures: American Colle ge 
of Rheumatology  Recommendations for Use in Clinical Practice, Arthritis Care & 
Research Vol. 64, No. 5, May  2012, pp 640 –647.
2. D ecernotinib drug information available online at
http://adisinsight.springer.com/drugs/800028324.
3. Baird, A. M., et al. (1998). "T cell development and activation in Jak3 -deficient mice." 
JLeukoc Biol 63(6): 669 -677.
4. Baslund, B., et al. (2005). "Targeting interleukin -15 in patients with rheumatoid 
arthritis: a proof -of-concept study ." Arthritis Rheum 52(9): 2686-2692.
5. F eist E, Burmester G (2013). Small molecules targeting JAKs —a new approach in the 
treatment of rheumatoid arthritis. Rheumatology  52 (8): 1352-
1357.
6. Churchman, S. M. and F. Ponchel (2008). "Interleukin -
7 in rheumatoid arthritis." 
Rheumatology  (Oxford) 47(6): 753-759.
7. Coenen JH M., (2007) Pharmacogenetics of anti-TNF treatment in patients with 
rheumatoid arthritis. July  2007 ,Vol. 8, No. 7, Pages 761-773.
8. Fleischmann, R. M., et al. (2015). "A randomized, double -blind, placebo -controlled, 
twelve -week, dose -ranging stud y of decernotinib, an oral selective JAK -3 inhibitor, as 
monotherap y in patients with active rheumatoid arthritis." Arthritis Rheumatol 67(2): 
334-343.
9.
Frucht, D. M., et al. (2001). "Unexpected and variable phenot ypes in a family  with 
JAK3 deficiency ." Gen es Immun 2(8): 422 -432.
10. Genovese, M. C., et al. (2016). "Efficacy  of VX -509 (decernotinib) in combination with 
a disease -modify ing antirheumatic drug in patients with rheumatoid arthritis: clinical 
and MRI  findings." Ann Rheum Dis.
11. Genovese, M. C., et al. (2016). "VX -509 (Decernotinib), an Oral Selective JAK -3 
Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis." 
Arthritis Rheumatol 68(1): 46-55.
12. Nosaka, T., et al. (1995). "Defective ly mphoid development in mice lacking Jak3." 
Science 270(5237): 800 -802.
13.
Olaharski, A.J., et al. (2009) “Identification of a kinase profile that predicts 
chromosome damage induced b y small molecule kinase inhibitors.” PL oS 
computational biology  5:e1000446.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 8214. O'Shea, J. J., et al. (2013). "Janus kinase inhibitors in autoimmune diseases." Ann 
Rheum Dis 72 Suppl 2: ii111 -115.
15. Saag, K. G., et.al., (2008), American College of Rheumatology  2008 recommendations 
for the use of nonbiologic and biologic disease -modify ing antirheumatic drugs in 
rheumatoid arthritis. Arthritis & Rheumatism, June 2008 59 (6): 762–784.
16. Silman, A. J. and J. E. Pearson (2002). "Epidemiology  and genetics of rheumatoid 
arthritis." Arthritis Res 4 Suppl 3: S265-272.
17. Smolen, J. S., et al. (2010). "EULAR recommendations for the management o f 
rheumatoid arthritis with sy nthetic and biological disease- modify ing antirheumatic 
drugs." Ann Rheum Dis 69(6): 964 -975.
18. Tanaka, Y. (2015). "Recent progress and perspective in JAK inhibitors for rheumatoid 
arthritis: from bench to bedside." J Biochem 158 (3): 173 -179.
19. Rojas -Zuleta, W. G. and G. Vasquez (2016). "Th9 ly mphocy tes: A recent history  from 
IL-9 to its potential role in rheumatic diseases." Autoimmun Rev 15(7): 649 -655.
20. Willemze, A., et al. (2012). "The influence of ACPA status and characteristics on the 
course of RA." Nat Rev Rheumatol 8(3): 144- 152.
21. Yang, X. K., et al. (2015). "Therapeutic potential of IL- 15 in rheumatoid arthritis." Hum 
Immunol 76(11): 812 -818.
22. Arava(Leflunomide) Prescribing label. Revised July  2011. Available online at 
http:/
/www.accessdata.fda.gov/ drugsatfda_docs/label/2011/020905s022lbl.pdf .
23. van Riel, P. L ., et al. (2004). "Leflunomide: a manageable safet y profile." J Rheumatol 
Suppl 71: 21-24.
24. Aletaha, D., et al. (2010). "2010 Rheumatoid arthritis classification criteria: an 
American College of Rheumatology /European League Against Rheumatism 
collaborative initiative." Arthritis Rheum 62(9): 2569-2581.
25. Aletaha, D., et al. (2010). "2010 rheumatoid arthritis classification criteria: an American 
College of Rheumatology/European League Against Rheumatism collaborative 
initiative." Ann Rheum Dis 69(9): 1580 -1588.
26. Hochberg, M. C., et al. (1992). "The American College of Rheumatology  1991 revised 
criteria for the classification of global functional status in rheumatoid arthritis." Ar thritis 
Rheum 35(5): 498-502.
27. RA drug information wash out is available online at http://dudley group.nhs.uk/wp -
content/uploads/2014/07/Guidelines- for-rheumatology -patients -on-biologic -therap y-
V1.pdf .

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 8328. M ager, D. E., et al. (2003). "Dose equivalency  evaluatio n of major corticosteroids: 
pharmacokinetics and cell trafficking and cortisol dy namics." J Clin Pharmacol 43(11): 
1216 -1227.
29.
Sebb R, and M. Singer (2005). Oxford Handbook of Critical Care. Oxford University 
Press.
30. Deflazacort drug information available on line at 
www.cw.bc.ca/library /pdf/pamphlets/bcch388deflazacort.pdf .
31. Shapiro, G. G., et al. (1979). "Cloprednol therap y in steroid- dependent asthma." 
Pediatrics 63(5): 747 -753.
32. Brune K. Chapter 3. Drug therap y today. In: Laufer S, Gay S, Brune K, editors. 
Inflammation and rheumatic diseases: the molecular basis of novel therapies. Stuttgart, 
German y: Georg Thieme Verlag; 2003: p. 69-92.
33. Adapted from Twy cross, R., et al. (1998). Palliative Care Formulary . Abingdon: 
Radcliffe Medical Press.
34. Adapted from Twy cross, R. (1994). Pain relief in advanced cancer. Edinburgh: 
Churchill L ivingstone.
35. Fries JF. (1983) “The assessment of disability: from first to future principles.” Br J 
Rheumatol 22(supple):48 -58.
36. Phan, N. Q., Blome C., et al. (2012). "Assessment of pruritu s intensity : prospective 
study  on validity  and reliability  of the visual analogue scale, numerical rating scale and 
verbal rating scale in 471 patients with chronic pruritus." Acta Derm Venereol 92(5): 
502-507.)

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 84Appendix 1.Abbreviations 
This following is a list of abbreviations that may  be used in the protocol. 
Abbreviation Term
AE adverse event
ACR american college of rheumatology
ACPA anti-citrullinated protein antibodies 
ALT alanine aminotransferase
ANCOVA analysis of covariance
AST aspartate aminotransfe rase
AUC area under the curve
ATP adenosine triphosphate
BA bioavailability
BID twice a day
BBS biospecimen banking s ystem
BP blood pressure
Cmax peak or maximum observed concentration
CK creatine kinase
CMV cytomegalovirus
CRF case report form
CSA clinical study  agreement
CSR clinical study  report
CT computerised t omography
CTA clinical trial application
CTCAE common terminology  criteria for a dverse e vents
CYP cytochrome p
DCT data collection tool
DILI drug-induced liver injury
DMARD disease -modify ing antirheumatic drugs 
DNA deoxy ribonucleic acid
DU dispensable unit
EBV epstein-barr virus
EC ethics committee
ECG electrocardiogram
eGFR estimated glomerular filtration rate
EDP exposure during pregnancy
EOS end of study
EU europea n union
EudraCT european clinical trials d atabase
EULAR european league against r heumatism 
FACS fluorescence -activated cell sorting
FDA food and drug administration 
FIH first in human

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 85Abbreviation Term
FSH follicle -stimulating hormone
FU follow up
fu fraction unbound
GCP good c linical practice
GGT gamma -glutamy l transferase
GST glutathione -S-transferase
HAQ- DI health assessment questionnaire – disability  index
HBcAb hepatitis B core antibod y
HBsAg hepatitis B surface antigen
HBcAb hepatitis B core antibod y
HIV human immunodeficiency virus
hsCRP high-sensitivity  C-reactive protein
HSV herpes simplex virus
IC50 50% inhibitive concentration
ICH international conference on harmonisation
ID identification
IgA, G, M, E immunoglobulin of the A, G, M , E isoty pes
IGRA interferon -gamma release assay
IL interleukin  
IND investigational new drug application
IFN interferons 
INR international normalized ratio
IP investigational product
IRB institutional review board
IRC internal review committee
IRT interactive response technology
ITT intent to treat
IUD intrauterine device
IV intravenous
IWR interactive web response
JAK janus kinase 
K2EDTA dipotassium ethy lenediaminetetraacetic acid
LFT liver function test
LOAEL lowest observed adverse effect level
LSLV last subject last visit 
MAD multiple ascending dose
MCP metacarpophalangeals
MRI magnetic resonance imaging
N/A not applicable
NOAEL no observed adverse effect level
NRS numeric rating scale
NSAID nonsteroidal anti- inflammatory  drugs
PAAP patient assessment of arthritis pain

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 86Abbreviation Term
PCD primary  completion date
PD pharmacod ynamics(s)
PGx pharmacogenomics(s)
PhGA physician ’sglobal assessment
PI principal investigator
PK pharmacokinetic
PO per os (oral)
PT prothrombin time
PtGA patient ’sglobal assessment
RA rheumatoid arthritis
RNA ribonucleic acid
SAE serious adverse event
SAD single ascending dose
SAP statistical analy sis plan
SC subcutaneous
SDAI simple disease activity  index
SJC swollen joint count
SLE systemic lupus e rthematosus 
SOP standard operating procedure
SRSD single reference safet y document
SUSAR suspected unexpected serious adverse reaction
TBili total bilirubin
TEAE treatment emergent adverse event
TJC tender joint count
TNF tumor necrosis factor
TNF tumor necrosis factor alpha
TNFi TNF inhibitors 
UC ulcerative colitis
UGT uridine 5’ -diphospho- glucuronos yltransferase
ULN upper limit of normal
US United States
VAS visual analog scale
VZV varicella z oster virus 
WBC white blood cells
WONCBP wome n of non- childbearing potential

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 87Appendix 2. 2010 ACR/EULAR Classification Criteria for Rheumatoid Arthritis24,25
Presented below are the 2010 American College of Rheumatology ( ACR)/European League 
Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis. 
Target population (Who should be tested?) must have:
1)  have at least 1 joint with definite clinical synovitis (swelling)*
2)  with the synovitis not better explained by another disease†
Classification criteria for RA (score- based algorithm: add score of categories A –D;
a score of _6/10 is needed for classification of a patient as having definite RA)‡
A. Joint involvement§ SCORE (A) ______
1 large joi nt¶ 0
2-10 large joints 1
1-3 small joints (with or without involvement of large joints)# 2
4-10 small joints (with or without involvement of large joints) 3
>10 joints (at least 1 small joint)** 5
B. Serology (at least 1 test result is needed for classification)†† SCORE (B) ______
Negative RF and 
negative ACPA 0
Low-positive RF or low -positive ACPA 2
High -positive RF or high-positive ACPA 3
C. Acute -phase reactants (at least 1 test result is needed for classification)‡‡ SCORE (C) ______
Normal CRP and normal ESR 0
Abnormal CRP or abnormal ESR 1
D. Duration of symptoms§§ SCORE (D) ______
<6 weeks 0
6 weeks 1
TOTAL SCORE (A+B+C+D) ___________
A TOTAL Score of 6/10 is needed for classificat ion of a patient as having definite RA)‡
* The criteria are aimed at classification of newly presenting patients.   In addition, patients with 
erosive disease typical of rheumatoid arthritis (RA) with a history compatible with prior fulfillment 
of the 2010 criteria should be classified as having RA.   Patients with longstanding disease, 
including those whose disease is inactive (with or without treatment) who, based on retrospectively 
available data, have previously fulfilled the 2010 criteria should be class ified as having RA.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 88† Differential diagnoses vary among patients with different presentations, but may include conditions 
such as systemic lupus erythematosus, psoriatic arthritis, and gout.   If it is unclear about the 
relevant differential diagnoses to co
nsider, an expert rheumatologist should be consulted.
‡ Although patients with a score of <6/10 are not classifiable as having RA, their status can be 
reassessed and the criteria might be fulfilled cumulatively over time.
§ Joint involvement refers to any swollen or tender joint on examination, which may be confirmed by
imaging evidence of synovitis.   Distal interphalangeal joints, first carpometacarpal joints, and first
metatarsophalangeal joints are excluded from assessment .  Categories of joint distribut ion are 
classified according to the location and number of involved joints, with placement into the highest 
category possible based on the pattern of joint involvement.
¶ “Large joints” refers to shoulders, elbows, hips, knees, and ankles.
# “Small joints” refers to the metacarpophalangeal joints, proximal interphalangeal joints, second 
through fifth metatarsophalangeal joints, thumb interphalangeal joints, and wrists.
** In this category, at least 1 of the involved joints must be a small joint; the other j oints can include 
anycombination of large and additional small joints, as well as other joints not specifically listed 
elsewhere (eg, temporomandibular, acromioclavicular, sternoclavicular, etc.).
†† Negative refers to IU values that are less than or equa
l to the upper limit of normal (ULN) for the
laboratory and assay; low -positive refers to IU values that are higher than the ULN but 3times the 
ULN for the laboratory and assay; high -positive refers to IU values that are >3times the ULN for 
thelaboratory and assay.  Where rheumatoid factor (RF) information is only available as positive or 
negative, a positive result should be scored as low -positive for RF.  ACPA= anti -citrullinated 
protein antibody.
‡‡ Normal/abnormal is determined by local laboratory s tandards.   CRP = C -reactive protein; 
ESR =erythrocyte sedimentation rate.
§§ Duration of symptoms refers to patient self -report of the duration of signs or symptoms of 
synovitis (eg, pain, swelling, tenderness) of joints that are clinically involved at th e time of 
assessment, regardless of treatment status.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 89Appendix 3. Criteria for Classification of Functional Status in Rheumatoid Arthritis26
Class I : Completely  able to perform usual activities of daily  living (self -care, v ocational, and 
avocational).
Class II : Able to perform usual self-care and vocational activities, but limited in avocational 
activities.
Class III : Able to perform usual self -care activities, but limited in vocational and avocational 
activities.
Class IV : Limited in ability  to perform usual self- care, vocational, and avocational activities.
Usual self -care activities including dressing, feeding, bathing, grooming, and toileting.  
Avocational (recreational and/or leisure) and vocational (work, school, homema king) 
activities are patient -desired and age -and sex -specific.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 90Appendix 4.Prohibited Concomitant Medications
This is not an all -inclusive list.  Study personnel should stay  current and consult with their 
pharmacy  to exclude all concomitant medications that are eit her moderate to potent CYP3A 
inhibitors or inducers.
Moderate to Potent CYP3A Inhibitors * Moderate to Potent CYP3A 
Inducers **
Amprenavir Avasimibe #
Amiodarone Bosentan
Aprepitant Barbiturates
Atazanavir Carbamazepine #
Boceprevir Efavirenz 
Casopitant Etravirine
Cimetidine Mitotane #
Ciprofloxacin Modafinil
Clari thromycin # Nafcillin
Cobicistat # Phenobarbital #
Conivaptan # Phenytoin #
Darunavir Rifabutin #
Diethyldithiocarbamate Rifampin #
Diltiazem St. John’s Wort #
Dronedarone Talviraline
Elvitegravir #
Erythromycin
Fluconazole
Fluvoxamine
Imatinib
Indinavir #
Itraconazole #
Ketoconazole#
Lopinavir #
Mibefradil #
Mifepristone (RU486)
Nefazodone #
Nelfinavir #
Norfloxacin
Posaconazole #
Ritonavir #
Saquinavir#
Schisandra sphenanthera
Telaprevir
Telithromycin#
Tipranavir#
Tofisopam
Troleandomycin#
Verapamil
Voriconazole#
* All prohibited drugs that are CYP3A inhibitors require at least a 7 day or 
5half-lives (whichever is longer) w ashout prior to the first dose of study drug.  
Note: Amiodarone requires discontinuation at least 290 days (~5 half-lives, 
half-life averages ~58 days) prior to the first dose of study drug.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 91** All prohibited drugs that are CYP3 A inducers require at least a 28 day or 
5half-lives (whichever is longer) w ashout prior to the first dose of study drug.
# Notated as potent inhibitors or inducers. 
It is recommended that subjects avoid consumption of grapefruit juice exceeding 
8ounces (~240 ml) total in a day while in the study.
In a situation where appropriate m edical care of a subject requires the use of a 
prohibited CYP3A inhibitor or inducer:
Moderate to potent inhibitors and inducers of CYP3A are not permitted in the study 
EXCEPT in emergency situations requiring no more than one day of administration.  
Note: Amiodarone and mitotane are not permitted for any duration due to their long 
half-lives.   Topical (including skin or mucous membranes) application of 
antimicrobial and antifu ngal medications is permitted.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 92Appendix 5.Guidelines for Monitoring and Discontinuations
These guidelines for subject safety  monitoring and discontinuation are to be applied to all 
subjects in this study .  Additional individual subject monitoring is at the discreti on of the 
investigator and dependent on any  perceived safety
 concerns.  Unscheduled clinical labs may  
be obtained at an y time during the study  to assess such concerns, and a subject may  be 
withdrawn at an y time at the discretion of the investigator.
Monitoring
The following laboratory abnormalities require re -testing within 1 week:
Absolute neutrophil count < 2000 /mm3;(< 2 x 109/L)
Hemoglobin <9.0 g/dL ;
Platelet count below <100,000/mm3;
(<100 x 109/L)
Lym phocy te counts <500 lymphocy tes/mm3; (<0.5x109/L)
Any single AST and/or AL T elevation 3times the upper limit of normal (repeat 
laboratory  testing should include albumin, creatine kinase, total bilirubin, direct 
and indirect bilirubin, GGT, PT [prothrombin time] with I NR [international 
normalized ratio], a nd alkaline phosphatase), regardless of the total bilirubin.  
(Please note that 3 times the upper limit of normal increases in ALT, AST need 
confirmation on separate blood draw before undertaking thorough evaluation for 
liver injury )
;
Allpotential treatme nt-related reports of rash will be followed up until resolution or in
agreement with Pfizer.  
Positive urine -hCG test, the subject will have study  drug interrupted and a serum 
sample collected on the same day  (or as soon as possible) and submitted to th e central 
laboratory  for -hCG testing.
Discontinuation
The sponsor’s Clinical team should be notified as soon as possible and subject t reatment will 
be discontinued and the subject withdrawn from this study  for:
Two sequential hemoglobin value <8.0 g/dL o r one that drops 2 g/dL  below baseline
Two sequential absolute neutrophil counts <750/mm3; (<0.75 x 109/L)
Two sequential platelet counts <75,000/mm3;(<75x 109/L)
Two sequential lymphocy te counts <500 lymphocy tes/mm3; (<0.5x109/L)

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 93Two sequential AST or ALT elevation 3times the upper limit of normal with at 
least one total bilirubin value 2times the upper limit of normala
Two sequential AST or ALT elevation 3 times the upper limit of normal 
accompanied b y signs or symptoms consistent with hepatic in jurya
Two sequential AST or ALT elevation 5times the upper limit of normal, regardless 
of total bilirubin or accompany ing signs or s ymptomsa
Serious infections, defined as an y infection (viral, bacterial, and fungal) requiring 
parenteral antimicrobial th erapy, hospitalization for treatment, or meeting other 
criteria that require the infection to be classified as serious adverse event
Other serious or severe AEs, at the discr etion of the investigator or sponsor
Female subjects found to be pregnant during t he study ;For women of child -bearing 
potential with any  positive urine -hCG test, the subject will have study  drug 
interrupted and a serum sample submitted to the central laboratory  for -hCG testing
Subjects who are treated with any  prohibited medication during the course of the 
study
Serious or severe drug -related rash at the discretion of the investigator or sponsor . 
(See Section 7.2.11)
Subjects who require rescue doses of acetaminophen/pa
racetamol or opioid for more 
than 10 consecutive day s or within the last 7 days before the last dose should be 
discontinued from the trial;
a In each case, there is a need for additional investigations, such as revie w of ethanol, recreational 
drug and die tary supplement consumption; testing for acute hepatitis A, B or C infection and 
biliary tract imaging should be promptly discussed with the Pfizer medical monitor or designee.
If a patient has an y clinically significant, treatment emergent abnormalities a t the conclusion 
of the study , the medical monitor (or designated representative) should be notified and every  
effort should be made to arrange follow- up evaluations at appropriate intervals to document 
the course of the abnormality. All abnormal laborator y events of clinical significance should 
be followed until the laboratory values have returned to the normal or baseline levels or is 
otherwise cons idered stable by  the i nvestigator.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 94Appendix 6.Disease Activity Score (DAS) Assessments1
DAS -28-4(CRP) Assessment
The formula for calculation of DAS28 -4(CRP) using 4 components:
Swollen Joints (0 –28);
Tender Joints (0
–28);
CRP
Patient’s Global Assessment of Arthritis (P tGA) (0 – 100 mm VAS).
DAS28-4 (CRP)= 0.56 sqrt (DAS 28 tender joint count) + 0.28 sqrt (DAS 28 swollen joint 
count) + 0.36 ln(CRP [mg/L ] +1) + 0.014 (PtGA [mm]) + 0.96
DAS -28-4 (ESR) Assessment
The formula for calculation of DAS28 -4(ESR) using 4 components:
Swollen Joints (0 –28);
Tender Joints (0
–28);
Erythrocyte Sedimentation Rate (ESR);
Patient’s Global Assessment of Arthritis (PtGA) (0 – 100 mm VAS).
DAS28-4 (ESR)= 0.56 sqrt (DAS 28 tender joint count) + 0.28 sqrt (DAS 28 swollen joint 
count) + 0.70 ln(ESR [mg/L ] + 0.014 (PtGA [mm]) 

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 95Appendix 7. Patient’s Assessm ent of Arthritis Pain (PAAP)
MY PAIN AT THIS TIME IS:
(PLEASE MAKE AN X MARK ON THE LINE BEL OW.)
No   ________________________________________________________ Most Severe
Pain Pain
[Note: Scale will be 100 mm in length]

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 96Appendix 8.Patient’s Global Assessment (PtGA) of Arthritis
CONSIDERING ALL THE WAYS YOUR ARTHRITIS AFFECTS YOU, HOW ARE 
YOU FEELING TODAY?
(PLEASE MAKE AN X MARK ON THE LINE BELOW.)
Very    ______________________________________________________ Very  
Well Poorly
[Note: Scale will be 100 mm in length]

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 97Appendix 9.Physician’s Global Assessment (PhGA) of Arthritis
THE PATIENT’S ARTHRITIS AT THIS TIME IS:
(PLEASE MAKE AN X MARK ON THE LINE BEL OW.)
Very    ______________________________________________________ Very
Good Poor
[Note: Scale will be 100 mm in length]

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 98Appendix 10.Oral Corticosteroid Equivalents28,29,30,31,32
The following is a summary  of corticosteroid equivalents.
Oral corticosteroids –subjects alread y taking oral corticosteroids must be on a stable dose of 
10mg/day  of prednisone or equivalent for at least 4 weeks prior to first dose of study  drug. 
Compound Equivalent Dose (mg)
Prednisone 10
Prednisolone 10
6-methy lprednisolone 8
Triamcinolone 8
Betamethasone 1.2
Dexamethasone 1.5
Hydrocortisone 40
Cortisone 50
Deflazacort 12
Cloprednol 5
Predny lidene 12
Note: these dose re lationships apply  to oral administration.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 99Appendix 11.Allowed Op ioids and Approximate Equivalent Morphine Doses Of 
Opioid Analgesics33,34
Common opioid analgesics
Drug Maximum A llowed 
Total Daily DoseRelative potency to 
oral morphineHalf -Life
Morphine 30 mg 1 1.5 – 4hrs
Hydrocodone (Vicodin, 
Lortab)30 mg 1 3.8 – 4.5 hrs
Hydromorphone 
(Dilaudid)7.5 mg 4 2.5hrs
Meperidine (Demerol, 
Pethidine)300 mg 0.1 3.2 – 3.7 hrs
Methadone (Dolophine, 
Methadose, Phy septone)10 mg 3.0 23hrs
Codeine (Paveral, 
Tylenol #2 and #3)200 mg 0.15 2.5 – 3.5 hrs
Oxycodone 
[Roxicodone; Percocet, 
Tylox]15 mg ~2 3.2hrs
Tramadol [Ultram, 
Zydol; Zamadol, 
Ultracet, Tramal]300 mg ~0.1 4.7 – 5.1 hrs
Propoxy phene HCl 
(Darvon, Darvocet, 
Doloxene) Propox yphene 
napsy late (Darvon- N, 
Darvocet -N 100)300mg 
propoxy phene HCl
400mg 
propoxy phene 
napsy late~0.1 6-12 hrs; 30-36 hrs. 
for active metabolite 
(norpropox yphene)
Sites should contact project team for acceptable alternative preparations and related data.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 100Appendix 12. Common Terminology Criteria for Adverse Events v4.03
(CTCAE) -Dermatology
The NCI Common Terminology  Criteria for Adverse Events v4.0 3is a descriptive 
terminology  that can be utilized for Adverse Ev ent (AE) reporting.  A grading (severit y) 
scale is provided for each AE term.  One page of the Dermatolog y/Skin Category  is 
presented, which contains listings for Pruritus, Rash/Desquamation, and Rash: 
Acne/acneiform.
Skin and subcutaneous tissue disorders
Grade
Adverse Event 1 2 3 4 5
Pruritus Mild or localized; 
topical intervention 
indicatedIntense or 
widespread; 
intermittent; skin 
changes from 
scratching (e g,
edema, papulation, 
excoriations, 
lichenification, 
oozing/crusts); oral 
intervention 
indicated; limiting 
instrumental ADLIntense or 
widespread; constant; 
limiting self care 
ADL or sleep; oral 
corticosteroid or 
immunosuppressive 
therapy indicated- -
Definition: A disorder characterized by an intense itching sensation.
Purpura Combined area of 
lesions covering 
<10% BSACombined area of 
lesions covering 10 -
30% BSA; bleeding 
with traumaCombined area of 
lesions covering 
>30% BSA; 
spontaneous bleeding- -
Definition: A disorder characterized by hemorrhagic areas of the skin and mucous membrane. Newer lesions appear 
reddish in color.   Older lesions are usually a darker purple color and eventually become a brownish -yellow color.
Rash acneiform Papules and/or 
pustules covering 
<10% BSA, which 
may or may not be 
associated with 
symptoms of pruritus 
or tendernessPapules and/or 
pustules covering 
10- 30% BSA, which 
may or may not be 
associated with 
symptoms of pruritus 
or tenderness; 
associated with 
psychosocial impact; 
limiting instrumental 
ADLPapules and/or 
pustules covering 
>30% BSA, which 
may or may not be 
associated with 
symptoms of pruritus 
or tenderness; 
limiting self care 
ADL; associated with 
local superinfection 
with oral antibiotics 
indicatedPapules and/or 
pustules covering any 
% BSA, which may 
or may not be 
associated with 
symptoms of pruritus 
or tenderness and are 
associated with 
extensive 
superinfection with 
IV antibiotics 
indicated; life-
threatening 
consequencesDeath
Definition: A disorder characterized by an eruption of papules and pustules, typically appearing in face, scalp, upper chest 
and back.
Rash maculo-papular Macules/papules 
covering
<10% BSA with or 
without symptoms 
(eg,pruritus, burning, 
tightness)Macules/papules 
covering 10
-30% BSA with or 
without symptoms 
(eg,pruritus, burning, 
tightness); limiting 
instrumental ADLMacules/papules 
covering
>30% BSA with or 
without associated 
symptoms; limiting 
self care ADL- -
Definition: A disorder characterized by the presence of macules (flat) and papules (elevated).   Also known as morbillform 
rash, it is one of the most common cutaneous adverse events, frequently affecting the upper trunk, spreading centripetally 
and associated with pruritus.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 101Rash/desquamation and ery thema multiforme progressing to Grade 2, acne/acneiform rash or 
pruritus progressing to Grade 3 are the severity levels for permanentl y discontinuing a 
subject from investigational product.
Pruritus progressing to Grade 2 sustained (>4 days) is cause to permanentl y discontinue 
investigational product.

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 102Appendix 13. HAQ- DI35
Health Ass essment Questionnaire - Disability Index (HAQ- DI)Stanford University 
1983 version:
In this section we are interested in learning how your illness affects your ability  to function in 
daily  life. 
Please check the response which best describes your usual abilities OVER THE PAST 
WEEK:
Without ANY 
difficultyWith SOME 
difficultyWith MUCH 
difficultyUNABLE 
to do
DRESSING & GROOMING
Are you able to:
-Dress yourself, including tying 
shoelaces and doing buttons?
-Sham poo y our hair?
ARISING
Are you able to:
-Stand up from a straight chair?
-Get in and out of bed?
EATING
Are you able to:
-Cut your meat?
-Lift a full cup or glass to your 
mouth?
-Open a new milk carton?
WALKING
Are you able to:
-Walk outdoors on flat ground?
-Clim b up five steps?

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 103Please check any AIDS OR DEVICES that you usually us e for any of these activities:
Cane Devices used for dressing (button hook, zipper pull, 
long-handled shoe horn, etc.)
Walker
Crutches Built up or special ute nsils 
Wheelchair Special or built up chair
Other (Specify:_______________)
Please check any categories for which you usually need HELP FROM ANOTHER 
PERSON:
Dressing and Groomi ng Eating
Arising Walking
Please check the response which best describes your usual abilities OVER THE PAST 
WEEK:
Without ANY 
difficultyWith SOME 
difficultyWith 
MUCH 
difficultyUNABLE 
to do
HYGIENE
Are you able to:
-Wash and dry your body?
-Take a tub bath?
-Get on and off the toilet ?
REACH
Are you able to:
-Reach and get down a 5 -pound object 
(such as a bag of sugar) from just above 
your head?
-Bend down to pick up clothing from the 
floor?

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 104Without ANY 
difficultyWith SOME 
difficultyWith 
MUCH 
difficultyUNABLE 
to do
GRIP
Are you able to:
-Open car doors?
-Open jars, which have been previously 
opened?
-Turn faucets on and off?
ACTIVITIES
Are you able to:
-Run errands and shop?
-Get in and out of a car?
-Do chores such as vacuuming or yard 
work?
Please check any AIDS OR DEVICES that you usually use for any of these activities:
Raised toilet seat Bathtub bar
Bathtub seat Long -handled appliances for reach
Jar opener (for jars previously 
opened)Long -handled appliances in bathroom
Other (Specify:_______________)
Please check any categories for which you usually need HELP FROM ANOTHER 
PERSON:
Hygiene Gripping and opening things
Reach Errands and chores

PF-06651600 
B7981006
Final Protocol Amendment 1, 26 October 2016
Page 105Appendix 14.Assessment of Itch (NRS)36
Severity of Pruritus
Select the number that best describes your itching over the past 24 hours (check one number 
only).
10 9 8 7 6 5 4 3 2 1 010 9 8 7 6 5 4 3 2 1 0
No 
itchingWorst 
possible 
itching
